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ABSTRACT 
In the present study we analyzed new neuroprotective therapeutical strategies in PD 
(Parkinson’s disease) and AD (Alzheimer’s disease). Current therapeutic strategies 
for treating PD and AD offer mainly transient symptomatic relief but it is still 
impossible to block the loss of neuron and then the progression of PD and AD. There 
is considerable consensus that the increased production and/or aggregation of α-
synuclein (α-syn) and β-amyloid peptide (Aβ), plays a central role in the pathogenesis 
of PD, related synucleinopathies and AD. Therefore, we identified antiamyloidogenic 
compounds and we tested their effect as neuroprotective drug-like molecules against 
α-syn and β-amyloid cytotoxicity in PC12. Herein, we show that two nitro-catechol 
compounds (entacapone and tolcapone) and 5 cathecol-containing compounds 
(dopamine, pyrogallol, gallic acid, caffeic acid and quercetin) with antioxidant and 
anti-inflammatory properties, are potent inhibitors of α-syn and β-amyloid 
oligomerization and fibrillization. Subsequently, we show that the inhibition of α-syn 
and β-amyloid oligomerization and fibrillization is correlated with the neuroprotection 
of these compounds against the α-syn and β-amyloid-induced cytotoxicity in PC12.  
Finally, we focused on the study of the  neuroprotective role of microglia and on the 
possibility that the neuroprotection properties of these cells could be use as 
therapeutical strategy in PD and AD. Here, we have used an in vitro model to 
demonstrate neuroprotection of a 48 h-microglial conditioned medium (MCM) 
towards cerebellar granule neurons (CGNs) challenged with the neurotoxin 6-
hydroxydopamine (6-OHDA), which induces a Parkinson-like neurodegeneration, 
with Aβ42, which induces a Alzheimer-like neurodegeneration, and glutamate, 
involved in the major neurodegenerative diseases. We show that MCM nearly 
completely protects CGNs from 6-OHDA neurotoxicity, partially from glutamate 
excitotoxicity but not from Aβ42 toxin.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 ALZHEIMER’S DISEASE  
 
In November 1901, Alois Alzheimer admitted at Anatomic Laboratory at Royal 
Psychatric Clinic of the University of Munich a 51-year-old patient named Auguste 
D. with progressive memory loss, language disturbances, visuospatial deficits, 
imaired judgment, motivation and neuropsychiatric synptoms as depression, anxiety, 
sleep disturbance and focal simptoms. After the death of the patient the brain was 
analysed and discovered neuritic plaques and neuropathological fibrillary tangles 
using the silver staining methods. In the 1906 Alois Alzheimer presented the clinical 
and neurophatological characteristics of a disease that subsequently Emil Krapeln 
named Alzheimer’s disease (AD). 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most 
common form of dementia among people age 65 and older. It has been estimated that 
1997, the disease affected more than 2 million older people in the United States alone 
(Brookmeyer et al., 1998). In the 2003, the Alzheimer’s Association estimed 4.5 
million US cases in the year 2000 and predicted that the number will rise 3-fold to 
13.2 million by 2050 (Hebert et al., 2000). 
 
 
 
1.1.1 Clinical features and Neuropathology 
 
AD characterized by early memory deficits, followed by progressive alteration of the 
major cognitive functions including deterioration of language as well as defects in 
visual and motor coordination, in judgement and emotions (Cummings et al., 2004).  
   2 
Alzheimer disease pathology are characterized into three broad chapter : lesions 
realted to accumulation used to detect and constitute the basis of diagnosis ;  losses of 
neurons and synapses and  finally reactive process (i.e. inflammation and plasticity). 
The lesions related to accumulation are mainly constituted by extracellular plaques 
(Fig 1.1a)  and intracellular aggregates of neurofibrillary tangles (NFTs) (Fig 1.1b).   
 
           a                                                   b 
            
Figure 1.1 deposits in AD. Extracellular amyloid plaques (a) and intracellular aggregates of 
neurofibrillary tangles (b). 
 
 
The AD brain is characterized by specific neuroanatomy alterations as neuronal cells 
and synapses loss at specific sites (Selkoe et al., 2002). The progressive loss of 
neurons results in athrophy of the affected regions of the brain, reported in Fig 1.2 and 
Fig 1.3.  
 
                           
Figure 1.2 Athrophy of the parietal and temporal cortex, hyppocampus and amigdala  in AD brain 
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Figure 1.3 Pet scan of normal brain (a) and Pet scan of AD brain 
 
The major neuropathological changes occur in the hippocampus, parietal and 
temporal cortex and subcortical structures including amygdala and nucleus basalis of 
Meynert (Arnold et al., 1991). Signs of  preclinical AD are first noticed in the 
entorhinal cortex, them proceed to the hippocampus. The affected regions begin to 
shrink as nerve cells die and changes can begin 10-20 years before symptoms appear. 
The memory loss is the first sign of AD (fig 1.4 a and d). In the mild to moderate AD 
the cerebral cortex begins to shrink as more and more neurons stop working and die. 
Mild AD signs can include memory loss, confusion, trouble handing money, poor 
judgement, mood changes and increased anxiety. Moderate AD signs can include 
increased memory loss and confusion, problems recognizing people, difficulty with 
language and thoughts, restlessness, agitation, wandering, and repetitive statements 
(fig 1.4 b and e). In severe AD, extreme shrinkage occurs in the brain. Patients are 
completely dependent on others for care. Symptoms can include weight loss, seizures, 
skin infections, groaning, moaning, or grunting, increased sleeping, loss of bladder 
and bowel control. Death usually occurs from aspiration pneumonia or other 
infections. Caregivers can turn to a hospice for help and palliative care (fig 1.4 c and 
f). 
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a                                              b                                           c                                          
 
d                                             e                                              f 
                                                
Figure 1.4 Preclinical AD (a and d) ; mild to moderate AD (b and c) ; severe AD (c and f). (National 
Institute on Aging, USA). 
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1.1.2 Amyloid plaques 
 
The amyloid plaques are dense deposits of protein and cellular material accumulated 
outside and around nerve cells. The major constituent of plaques is a 40-42 amino 
acids peptide termed Aβ (Aβ40 and Aβ42) that is derived by proteolytic cleavage from 
the amyloid precursor protein (APP), the general mechanism is reported in Fig 1.5.  
box1 (Jurgen Gotz and Lars M Ittner, 2008). The human APP gene was identified in 1987 localized on chromosome 21. More than  25 mutations  in  APP  gene  have  been  identified  that  are  causative  of  the hereditary  form  of  familial  AD  by  the  introduction  of  mutations  within  or flanking  the  Aβ  domain.    AD  was  found  associated  with    Down  syndrome  patients in which the APP gene is triplicated (Lemere et al., 1996). 
 
 
a                                          b                                           c 
     Figure 1.5 general mechanis of Aβ peptide  formation  from APP; APP sticks through the neuron membrane (a); enzymes cut the APP into fragments of protein, including beta‐amyloid(b); beta‐amyloid fragments come togheter in clumps to form plaques (c).   
The APP is a transmembrane protein  cleaved by different secretases. APP is first 
cleaved within the lumenal domain by β-secretase or γ-secretase resulting in the 
shedding of nearly the entire ectodomain and generation of memebrane-tethered β- or 
α-C-terminal fragments respectively. The β-fragment and γ-fragment are subsequently 
cleaved within the transmembrane domain by γ-secretase to release Aβ (4kDa) and p3 
(3kDa) peptides into the extracellular milieu. In addition the γ-secretase generates a 
cytoplasmic polypeptide termed AICD, showed in fig 1.6 (Thinakaran et al., 2008). 
Several zinc metalloproteinases such as BACE2 can cleave APP at the α-secretase site 
and the major β-secretase is a transmembrane aspartyl protease termed BACE1. The 
proteolytic cleavage of APP by β-secretase generates the amino terminus of Aβ and γ-
   6 
secretase induces its length (40 or 42 amino acids). γ-secretase is formed of four 
subunits : presenilin-1 or presenilin-2, nicastrin, APH-1 and PEN-2. The deposits 
contain a mixture of various Aβ isoforms. The Aβ40 peptide is much more prevalent 
than the aggregation-prone and damaging Aβ42 that contains two supplementary 
amino acids at the C-terminus of the peptide. (Duyckaerts et al., 2009). An increasing 
ratio of the full-length, Aβ42 peptide to te Aβ40 form is associated with the disease 
(Kumar-Singh et al.,  2006). The deposition of Aβ peptide is related to an imbalance 
between production and clearence of the amyloid protein (Glenner et al., 1984).  
                           
Figure 1.6 Proteolytic processing of APP. A, the schematic structure of APP is shown with the Aβ 
domain shaded in red and enlarged. The major sites of cleavage by α-, β-, and γ-secretases are 
indicated along with Aβ numbering from the N terminus of Aβ (Asp1). B, non-amyloidogenic 
processing of APP refers to sequential processing of APP by membrane-bound α- and γ-secretases. α-
Secretase cleaves within the Aβ domain, thus precluding generation of intact Aβ peptide. The fates of 
N-terminally truncated Aβ (p3) and AICD are not fully resolved. C, amyloidogenic processing of APP 
is carried out by sequential action of membrane-bound β- and γ-secretases. CTF, C-terminal fragment. 
(J Biol Chem. 2008 October 31; 283(44): 29615–29619) 
 
 
The function of Aβ peptide is still unknown, probably the peptide is physiologically 
produced at low concentration like a waste product. Recently studies showed that at 
picomolar concentration the Aβ peptide positively modulates synaptic plasticity and 
memory in hippocampus (Puzzo et al., 2008). The Aβ peptide is degradated by 
various emzymes as well as neprilysin and insulin degrading enzyme (IDE). 
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Neprilysin is a membrane-anchored zinc endopeptidase and the insulin-degrading 
enzyme is a thiol metalloendopeptidase that degrades small peptides such as insulin 
and monomeric Aβ. Oerexpression of neprilysin or insulin-degrading enzyme 
prevents plaque formation (Leissring et al., 2003). 
The amyloid cascade hypothesis (selkoe lesson from Alzheimer’s peptide) 
 
1.1.3 Types of  Aβ deposits in AD 
 
The identification of extracellular deposits of Aβ peptide has been revealed  by anti-
Aβ antibodies or by Congo red and thioflavine S staining. The deposits could be 
parenchymal deposits or vascular deposits. The parenchymal deposits differ for their 
shape and may be distinguished in diffuse, focal or stellate Aβ deposits. (Delaere et 
al., 1990). The stellate deposits are probably related to astrocytes and rarely studied. 
The focal type of deposits may be amyloid ( Congo red and thioflavine s positive). 
The diffuse Aβ deposits are usually large and ill-limited and in some regions of the 
brains the deposits are diffuse. The diffuse deposits have been found in the 
presubiculum, in the internal layers of the entorhinal cortex, in the striatum, in 
molecular layer of cerebellum and in the subpial region of the isocortex. The diffuse 
deposits have been found in subjects whose intellectual status had been evaluated 
normal to indicate that these lesions may not be directly toxic. (Duyckaerts et al., 
2009). The focal deposits showed dense and spherical accumulations of Aβ peptide 
and may be amyloid or not. The parenchymal deposits are associated with various 
proteins, lipids and cells  as well as ApoE produced by astrocytes and involved in 
cholesterol transport and the Apoε4 allele is considered a risk factor of AD ;  (Namba 
et al., 1991 ). the deposits are associated with ApoJ, also called clusterin, (Martin-
Rehrmann et al., 2005) with metals and components of the matrix like ICAM1 
(Verbeek et al., 1994). thrombospondin (Buee et al., 1992), heparan sulfate 
proteoglycan. The Cathepsin D, a lysosomal enzyme, is localized around the the 
plaques and it could be related to the activation of the endosomal-lysosomal pathway 
(Cataldo et al., 1990). 
Sometimes the Aβ deposits have been found in the vessel walls inducing lobar 
hemorrhages and small cortical infarcts. Mutation in APP gene has been found in 
hereditary cerebral hemorrhages ( Lewy et al., 1990) 
   8 
1.1.4 Tau accumulation 
 
Neurofibrillary tangles, which are filamentous inclusion in neurons occur in AD and 
other neurodegenerative disorders termed taupathies. The major component of the 
tangles is an abnormally hyperphosphorylated and aggregated form of tau. Usually, 
tau is involved in the stability of the microtubules and vescicle transport. 
Hyperphosphorylated tau self-associates into paired helical filament structures (Fig 
1.7). 
Neurons have an internal support structure partly made up of microtubules. The 
protein tau helps stabilize microtubules. In AD tau changes, causing microtubules to 
collapse and tau proteins clump togheter to form neurofibrillary tangles. 
               
            
Figure 1.7 Tau structure and function 
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1.1.5 Genetics 
The famlial AD (FAD) represent less than 1% of the total number of AD cases. 
Autosomal dominant mutations have been identified in three genes : APP, preselin1 
(PSEN1) and preselin2 (PSEN2) which are proteolytic subunits of the γ-secretase 
complex generating the C-terminus of Aβ. The vast majority of FAD patients bear 
mutations in the genes encoding PS1 and PS2 ; more than 130 mutations in the 
PENS1 and PENS 2 have been identified. Pathogenic puntiform mutations have been 
identified in APP,  and these mutation predominantly affect residues 22 and 23 
including Dutch (E22Q), Italian (E22K), Iowa (D23N), Flemish (A21G) and arctic 
(E22G) (Nilsberth et al., 2001),V717I London mutation (Goate et al.,), These 
mutations in APP aggregate faster than wild type the peptide (Kirkitadze et al., 2001). 
In the sporadic AD (SAD) various susceptibility genes have been identified including 
apolipoprotein E (APOE) (Bertram & Tanzi, 2005). 
The most prominent example of elevated Aβ concentration is the gene dosage effect 
in trisonomy 21 patients (Lemere et al., 1996). 
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1.2  PARKINSON’S DISEASE 
 
1.2.1 Clinical features and Neuropathology 
 
Parkinson's disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease (AD). PD affects 1% of people beyond 65 years of age with high 
prevalence in men. Although approximately 10% of cases affect people under age 40. 
PD was first formally described in 1817 by a London physician named James 
Parkinson. The major symptoms involve: uncontrollable resting tremor, rigidity with 
increase muscle tone and increase resistance to movement, postural instability, 
bradykinesia and gait disturbance, which vary between the patients. Usually these 
symptoms could be accompanied with dementia, depression, dystonia.  
Early pathological changes in PD include the selective loss of dopaminergic neurons 
of the substantia nigra pars compacta and other areas of the brain resulting in the 
degeneration of the nigro-striatal tract and loss of dopamine (Recchia rt al., 2004).  
Neuropathologically, PD is characterized by the formation of intraneuronal Lewy 
bodies (LBs) and Lewy neuritis (LNs), reported in Fig 1.8. LBs and LNs consist 
primarily of fibrillar aggregated of α-synuclein (α-syn) (Spillantini et al., 1997) . 
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Figure 1.8 a, Two pigmented nerve cells, each containing an α-synuclein-positive Lewy body (thin 
arrows). Lewy neurites (thick arrows) are also immunopositive. Scale bar, 20m. b, A pigmented nerve 
cell with two α-synuclein-positive Lewy bodies. Scale bar, 8m. c, α-Synuclein-positive, extracellular 
Lewy body. Scale bar, 4m. (Spillantini, et al., 1997). 
 
 
 
1.2.2  α-synuclein protein 
 
The α-synuclein is a cytosolic protein of 14 kDa, 140 amino acids, “natively 
unfolded”, present in extracellular amyloid plaques in some forms of Alzheimer’s 
disease patients. (Recchia et al., 2004) . 
The synuclein family include α-Syn, β-Syn and γ-Syn. α-Syn and β-Syn are 
predominantly expressed in brain at presynaptic terminals, particularly in the 
neocortex, hippocampus, striatum, thalamus, and cerebellum Figure 1.9 (Iwai et al., 
1995). The α-syn is high expressed in the substantia nigra and has been found 
overexpressed in breast and ovarian tumors (Lavedan et al., 1998). The α-syn gene 
has been mapped to the human chromosome 4q21, the β-Syn to the chromosome 5q35  
(Spillantini MG et al., 1995) and the γ-Syn to the chromosome 10q23 (Lavedan et 
al.,1998). 
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Figure 1.9 a, α-Synuclein-positive Lewy neurites in the substantia nigra. b, α -Synuclein-positive Lewy 
body (arrow) in pigmented nerve cell of the substantia nigra. c, Two α -synuclein-positive Lewy bodies 
in the cingulate cortex. d, Haematoxylin and eosin-stained section of substantia nigra with a pigmented 
nerve cell containing a Lewy body. Scale bar for a-d, 10       m. (Spillantini, et al., 1997). 
 
 
The sequence of α-synuclein protein can be subdivided in three domains: N-terminal 
domain, NAC domain and C-terminal domain, reported in figure 1.10. The N-
terminus domain is highly conserved (residues 1-65) include six copies of 11aa 
imperfect repeat that display variations of KTKEGV consensus sequence and can 
shift to an α-helical conformation that consist of two α-helixes. These amphipathic α-
helixes can bind to negatively charged phospholipids suggesting that the protein could 
be associated with the membrane. In the alpha-helix forming domain have been found  
two independent missense mutations, A53T and A30P, associated with autosomal 
dominant heritable early-onset PD (Clayton et al.,  1999).  These mutations are linked 
to the disease inducing the protein structure destabilization and the subsequently 
protein aggregation (Rochet et al.). 
The NAC region is a central hydrophobic domain (residues 66-95), involved in the 
aggregation of the protein for the shift of the random-coil to β-sheet structure (El-
Agnaf et al.,2002). This domain has been found in the plaques in AD (Gisson et al, 
2001). 
The C-terminus domain (residues 96-140) is primarily composed of acidic amino 
acids and is not very conserved between species. In the C-terminus domain have been 
identified several phosphorylation sites: Tyr-125, Tyr-133, Tyr-136 and Ser-129. The 
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Ser 129 has been found phosphorilated in synucleinopathy lesions, including LBs 
(Fujiwara  et al., 2002). 
 
  
 
               
 
Figure 1.10. Human α-syn sequence and domains. The imperfect KTKEGV repeats are shown by violet 
columns. Missense mutations at residues 30 (A30P) and 53 (A53T) are shown in red. Recchia et al., 
2004).  
 
 
Accumulating evidence from genetics, animal models, biochemical and biophysical 
studies suggest that α‐syn plays a central role in the initiation and/or progression of 
PD (Cookson et al., 2009) Mutations or increased expression of α‐syn are associated 
with early‐onset familial forms of PD (Chung et al.2003; Li et al., 2001; Zarranz et 
al., 2004). 
Overexpression of wild type and disease-associated mutants enhances α-syn 
aggregation and toxicity in several animal and cellular models of synucleinopathies 
(Chen et al., 2005); Lo Bianco et al., 2008; Masliah et al., 2000). In vitro studies have 
consistently shown that disease-associated mutations accelerate and enhance α-syn 
oligomerization (A30P, A53T and E46K) and/or fibrillization (A53T and E46K) (El-
Agnaf et al., 1998; Paleologou et al., 2008; Conway et al., 2000; Conway et al., 
2000). Despite these advances in our understanding of the molecular mechanism of 
α-syn aggregation and toxicity in vitro and in vivo, very little is known about the 1) 
normal function of α-syn; 2) the relative contribution of α-syn aggregation to the 
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pathogenesis of PD; 3) identity of the toxic α-syn species; 4) the exact mechanism by 
which α-syn contributes to the loss of dopaminergic neurons and PD pathology also 
remains poorly understood (Horwich et al.,2002; Losic et al., 2006; Morgan et 
al.,2004). 
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1.3 AMYLOID PROTEIN, AGGREGATION AND ANTIAMYLOID 
APPROACH IN NEURODEGENERATIVE DISEASE 
 
1.3.1 From misfolding proteins to protein deposition diseases 
 
Different human neurodegenerative disorders share common pathogenic mechanisms 
involving aggregation and accumulation of misfolding proteins in the Central 
Nervous System (CNS).  Proteins are the major components of the living cells, which 
play crucial role in the maintenance of life and the conversion of genetic informations 
into functional proteins is a central process in biology.  The proteins to assolve their 
functions undergo folding process to assume their three-dimensional structures and 
then adopt  the correct native state. The proteins are  synthetized on the ribosome  and 
the folding process can be a co-translational process or  occurs in the cytoplasm or in 
specific compartements such as mitochondria or endoplasmic reticulum (ER) after 
trafficking and traslocation through membranes. The cells have developed specific 
strategies to avoid that incompletely folded proteins are exposed to the solvent and 
then to inappropriate interactions with other molecules and macromolecules crowding 
in intracellular environment in the tranport (Ellis et al., 2001). To counteract these 
dangeres, cells have developed a sophisticated system of  protein quality control that 
trough degradation of aberrant or misfolded proteins contributes to a healthy 
intracellular environment. The degradation of proteins can be executed by different 
proteolytic system such as  lysosomal degradation, chaperone-mediated autophagy 
and substrate-specific degradation by ubiquitin-proteosome system (UPS). The UPS 
is revelant in the neuronal development and plasticity other than in neurodegenerative 
disease where a direct linkage between UPS malfunction and disease pathogenesis 
was associated with an accumulation of ubiquitin conjugates and other UPS-related 
components in the neuropathological hallmarks of many neurodegenerative disease ( 
van Tijin et al., 2008).  The  molecular chaperones are present in all type of cells and 
cellular compartments and they increase the efficency of the overall process by 
reducing the probability of competing reactions, particularly aggregation. Some 
chaperones interact with the nascent chains whereas others are involved in guiding 
later stages of the folding process (Dobson et al, 2003; Young et al., 2004).  
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Some proteins have the specific propensity to assume a pathogenic conformation 
which can become evident with the aging. In fact, a broad range of human diseases 
known as proetin misfolding disease arises from the failure of a specific peptide to 
adopt or remain in its native functional state. The misfolding diseases also known as 
 protein deposition diseases, include neurodegenerative conditions, such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), the spongiform 
encephalopathies, Hunghtington’s disease (HD), amyotrophic lateral sclerosis (ALS) 
and include systemic amyloidoses, such as light chain and lysozyme amyloidoses, 
familial amyloid polyneuropathy and dialysis-related amyloidosis, as well as localized 
amyloidoses, including type II diabetes and aortic medial amyloidosis, as summarized 
in table 1 and table 2 . Overall, more than 40 human protein deposition diseases have 
a distinct clinical profile and each associated with a single dominant amyloid protein 
or peptide that is prone to aggregate and form amyloid fibrils subsequently 
accumulate in deposits (Fig 1.11). Amyloids fibrils are derived from various 
amyloidogenic proteins that initially exist in either a « natively unfolded » or 
« naturally folded » state. α-synuclein protein accumulated in the Lewy bodies in PD, 
amiloyd polypeptide (IAPP) aggregates associated with diabetes mellitus type 2 and 
amyloid β-protein aggregates represent a group of polypeptides whose structures are 
predominantly random and this unfolded state allows the proteins to be readily self-
assembled into the fibrillar suprastructures. On the contrary  some amyloidogenic 
proteins retain their native structures before undergoing conformational transition and 
eventual fibril formation (Chiti et al., 2009). This group of proteins include prion, β2-
microglobulin, lysozyme, transthyretin (TTR) and a variable region of 
immunoglobulin light chain (VL), which are responsible for mad cow disease, 
dialysis-related amyloidosis, hereditary systemic amyloidosis, systemic amyloidosis 
and light-chain amyloidosis (Bhak et al., 2009). 
The first indication that protein misfolding and aggregation were involved in 
neurodegenerative diseases came from post-mortem neurophatological studies. In the 
post-mortem studies the misfolding proteins have been found accumulated in deposits 
(Fig 1.11). Support for a casual role of the protein misfolding in the diseases has come 
from genetic studies (Hardy et al., 1998). Mutations in the genes that encode for the 
misfolded proteins were associated with the manifestation of neurodegenerative 
diseases. In the 1991 a missense mutation in the amyloid precursor protein gene was 
associated with the familial AD (Goate et al., 1991). Subsequently, in the 1997, there 
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was the first association between the alpha-synuclein gene and familial PD 
(Polymeropoululos et al., 1997). In the same years genes encoding for misfolding 
proteins associated with HD ( Huntington’s Disease Collaborative Research Group 
(HDCRG) a novel gene containing a trinucleotide repeat that is unstable on 
Huntington’s disease chromosomes Cell (1993) 72: 971-983) prion disease (Hsiao et 
al., 1989) and SLA ( Rosen et al., 1993) were identified. Subsequently the generation 
of transgenic animal models with mutant forms of genes encoding the misfolding 
protein have provided evidence for the contribution of these proteins to disease 
pathogenesis (Soto et al., 2003). Transgenic mouse with overexpression of human 
amyloid protein precursor (APP) gene progressively developed cerebral amyloid 
deposits, neuritic dystrophy and behavioral alterations (Games et al., 1995). Similarly, 
transgenic mice overespressing human gene of α-synuclein showed several 
clinicophatological characteristics of PD as well as dopaminergic loss and inclusion 
body formation  (Masliah et al., 2000). Transgenic mouse with human mutaded SOD1 
gene developed motor neuron dysfunction and hyaline inclusion bodies in 
degenerating axons, muscle atrophy, astrocytic damage and loss of large myelinated 
axons of motor neurons (Gurney et al., 1994). In the same manner transgenic mice 
with human PrP gene overexpression resulted in spontaneous neurogical disease with 
spongiform degeneration (Hsiao et al., 1990). 
The amyloidogenic protein constituent differs among the various neurodegenerative 
diseases and the aggregates accumulate in early in the lifetime of the individual, but 
only manifest clinical simptoms in middle or later life.  
The deposition of these aggregated material can occur in a large variety of organs and 
tissues; as summarized in table 1.1 the protein deposition diseases can be also 
grouped into neurodegenerative conditions, in which aggregation occurs in the brain, 
non-neuropathic localized amyloidoses, in which aggregation occurs in a single type 
of tissue other than the brain, and nonneurophatic systemic amyloidoses in which 
aggregation occurs in multiple tissue, showed in table 1.2. 
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Figure 1.11 Cerebral aggregates in neurodegenerative diseases : Extracellular amyloid 
plaques (white arrows) and intracytoplasmic neurofibrillary tangles (yellow arrows) 
are the phatological signature of AD. Intracytoplasmic aggregates are tipically present 
in the neurons of people affected by PD and SLA. Intranuclear inclusions of 
huntingtin are observed in Huntington’s disease patients and extracellular prion 
amyloid plaques that are located in different brain regions are present in some cases 
of transmissible spongiphorm encephalophathy. In spite of the different protein 
compositions, the ultrastructure of these deposits seems to be similar and composed 
mainly of a network of fibrillar polymers (centre)(Soto et al., 2003). 
 
 
Some of these conditions, such as Alzheimer’s and Parkinson’s diseases are 
predominantly sporadic (labeled in c in Table1.1 and Table 1.2), but genetic forms are 
caused by mutations in the gene encoding the amyloidogenic protein (mutations in 
alpha-syn or other mutations). Other conditions, such as the lysozyme and fibrinogen 
amyloidoses, arise from specific mutations and are hereditary (labeled in d in 
Table1and Table 1.2). In addition to sporadic (85%) and hereditary (10%) forms, 
spongiform encephalopathies can also be transmissible (5%) in humans as well as in 
other mammals (Chiti et al., 2006 ; Chiti et al., 2009).  
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a  Data  refer  to  the  number  of  residues  of  the  processed  polypeptide  chains  that  deposit  into aggregates, 
not of the precursor proteins.b According to Structural Classification Of Proteins (SCOP), these are the 
structural class and fold of the native states of the processed peptides or proteins that deposit into 
aggregates prior to aggregation.c Predominantly sporadic, although in some cases hereditary forms 
associated with specific mutations are well documented.d Predominantly hereditary, although in some 
cases sporadic forms are documented.e Five percent of the cases are transmitted (e.g., iatrogenic).f 
Fragments of various lengths are generated and have been reported to be present in ex vivo fibrils.g 
Lengths shown refer to the normal sequences with nonpathogenic traits of polyQ.h Length shown is for 
ataxin-1.i The pathogenic mutation converts the stop codon into a Gly codon, extending the 77-residue 
protein by 21 additional residues.j Human insulin consists of two chains (A and B, with 21 and 30 
residues, respectively) covalently linked by disulfide bridges.k Medin is the 245–294 fragment of  
 
 
 
Table 1.1  Human diseases associated with formation of extracellular amyloid deposits or 
intracellular inclusions with amyloid-like characteristics in the neurodegenerative diseases 
Disease  Aggregating protein or peptide  
Number of 
residues a  
Native structure of protein or peptide 
b  
Alzheimer's disease c  Amyloid β peptide 40 or 42 f  Natively unfolded 
Spongiform encephalopathies c,e  Prion protein or fragments 
thereof 
253 Natively unfolded (residues 1–120) and α-
helical (residues 121–230) 
Parkinson's disease c  α-Synuclein 140 Natively unfolded 
Dementia with Lewy bodies c  α-Synuclein 140 Natively unfolded 
Frontotemporal dementia with 
Parkinsonism c  
Tau 352–441 f  Natively unfolded 
Amyotrophic lateral sclerosis c  Superoxide dismutase 1 153 All-β, Ig like 
Huntington's disease d  Huntingtin with polyQ 
expansion 
3144 g  Largely natively unfolded 
Spinocerebellar ataxias d  Ataxins with polyQ expansion 816 g,h  All-β, AXH domain (residues 562–694); the 
rest are unknown 
Spinocerebellar ataxia 17 d  TATA box-binding protein 
with polyQ expansion 
339 g  α+β, TBP like (residues 159–339); unknown 
(residues 1–158) 
Spinal and bulbar muscular 
atrophy d  
Androgen receptor with polyQ 
expansion 
919 g  All-α, nuclear receptor ligand-binding 
domain (residues 669–919); the rest are 
unknown 
Hereditary dentatorubral-
pallidoluysian atrophy d  
Atrophin-1 with polyQ 
expansion 
1185 g  Unknown 
Familial British dementia d  ABri 23 Natively unfolded 
Familial Danish dementia d  ADan 23 Natively unfolded 
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Table 1.2  Human diseases associated with formation of extracellular amyloid deposits or 
intracellular inclusions with amyloid-like characteristics in non neuropathic systemic 
amyloidoses 
Nonneuropathic systemic amyloidoses       
AL amyloidosis c  Immunoglobulin light chains or fragments 90 f  All-β, Ig like 
AA amyloidosis c  Fragments of serum amyloid A protein 76–104 f  All-α, unknown fold 
Familial Mediterranean fever c  Fragments of serum amyloid A protein 76–104 f  All-α, unknown fold 
Senile systemic amyloidosis c  Wild-type transthyretin 127 All-β, prealbumin like 
Familial amyloidotic polyneuropathy d  Mutants of transthyretin 127 All-β, prealbumin like 
Hemodialysis-related amyloidosis c  β2-microglobulin 99 All-β, Ig like 
ApoAI amyloidosis d  N-terminal fragments of apolipoprotein AI 80–93 f  Natively unfolded 
ApoAII amyloidosis d  N-terminal fragment of apolipoprotein AII 98 i  Unknown 
ApoAIV amyloidosis c  N-terminal fragment of apolipoprotein AIV 70 Unknown 
Finnish hereditary amyloidosis d  Fragments of gelsolin mutants 71 Natively unfolded 
Lysozyme amyloidosis d  Mutants of lysozyme 130 α+β, lysozyme fold 
Fibrinogen amyloidosis d  Variants of fibrinogen α-chain 27–81 f  Unknown 
Icelandic hereditary cerebral amyloid 
angiopathy d  
Mutant of cystatin C 120 α+β, cystatin like 
Nonneuropathic localized diseases       
Type II diabetes c  Amylin, also called islet amyloid polypeptide 
(IAPP) 
37 Natively unfolded 
Medullary carcinoma of the thyroid c  Calcitonin 32 Natively unfolded 
Atrial amyloidosis c  Atrial natriuretic factor 28 Natively unfolded 
Hereditary cerebral haemorrhage with 
amyloidosis d  
Mutants of amyloid β peptide 40 or 42 
f  
Natively unfolded 
Pituitary prolactinoma Prolactin 199 All-α, 4-helical 
cytokines 
Injection-localized amyloidosis c  Insulin 21 + 30 j  All-α, insulin like 
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1.3.2 Pathological characterization of protein aggregated deposits 
 
The neurodegenerative diseases are charaterized pathologically by the deposition of 
insoluble filamentous aggregates in extracellular plaques or intracellular inclusions in 
the CNS as reported in Figure 1.12. The advances of the human genetics, cellular 
biology and biochemistry allowed to identify the protein constituents of the deposits. 
The cytopathological hallmarks of Parkinson’s disease are the Lewy bodies (LBs) and 
Lewy neurites (LNs), in Figure 1.12d. Missense mutations in the gene that encodes 
for the α-synuclein was identified in family with autosomal-dominant parkinsonism 
by linkage analysis and positional cloning studies (Polymeropoulos et al., 1997). 
Subsequently, an immunohistochemistry analysis of the substantia nigra and cingulate 
cortex extract from patients with Parkinson’s disease, allowed the identification of the 
the α-synuclein protein as the major protein constituent of the LBs and LNs     
(Spillantini et al., 1997 ; Barba et al., 1998). In a similar manner trough discover of 
causative genes associated with the specific neurodegererative disorder was possible 
the identification of aggregation-prone proteins in disorders such as ALS (Rosen et 
al., 1993 ; Deng et al., 1993) and HD in Fig 1.12e (Hungtington’s Disease 
Collaborative Research Group A novel gene containing a trinucleotide repeat that is 
expanded and unstable on Huntington’s disease chromosomes., Cell 1993, 72 971-
983). The pathological hallmarks of Alzheimer’s disease are extracellular plaques of 
amyloid-β peptide (Aβ) and neurofibrillar tangle respectively reported in Figure 1.12 
a-b. In the 1980s, the Aβ peptide was before isolated and purified from microvascular 
amyloid deposits from the meninges of AD brains (Glenner et al., 1984) and 
afterwards  from  amyloid plaques core of the post-mortem AD cortices (Masters et 
al.,1985). In the same years Tau protein phosphorilated was discovered to be the 
constituent of the neurofibrillar tangle (Haass et al., 2007). Many type of Aβ-deposits 
were identified using the immunohistochemistry as well as parenchyma deposits or 
vascular deposits. 
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Figure 1.12 Panel a shows Alzheimer’s disease with Aβ-positive senile plaques, and panel b 
shows tau-positive neurofibrillary tangles, neurophil threads and dystrophic neurites. Panel c 
shows PrP deposits in the cerebellum of a Creutzfeldt-Jacob case. Panel d shows substantia 
nigra of a Parkinson’s disease case with an α-synuclein-positive Lewy body (right) and Lewy 
neurites (left). Panel e shows a ubiquitin-positive huntingtin inclusion in a case of 
Huntington’s disease. The scale bar represents 100µm. (Haass et al., 2007) 
 
The extracellular deposits found in patients suffering from any of the amyloid 
diseases have a major protein component, the misfolding proteins, that form the core 
and then additional associated species, including metal ions, glycosaminoglycans, the 
serum amyloid P component, apolipoprotein E, collagen, and many other (Hirschfield 
et al., 2005). 
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1.3.3 General properties of amyloid fibrils 
 
Aminoacid composition and sequence analysis of the amyloid proteins revealed that 
each amyloid disorder was associated with a particular protein or peptide. In the 
neurodegenerative disorder  a specific misfolding protein is unable to adopt or  remain 
in its native state and it is converted from its soluble state into well-organised fibrillar 
aggregates with amyloid-like characteristics and resistant to degradation, reported in 
Fig 1.13. The characteristics of the soluble forms of proteins involved are very varied 
from globular proteins to largely unstructured peptide molecules with different 
primary sequences and with heterogeneity in secondary srtucture composition or 
chain length but they shared characteristics in commom and these characteristics 
confers the fibrillar, proteolytic resistant and insoluble properties to all form of 
amyloid. 
Amyloid deposits have specific optical behaviour, they have the ability to bind 
specific fluorescent dyes such as Congo red  (Puchteler et al., 1961 ; Puchtler et al., 
1965;) and Thioflavine T (LeVine et al., 1993) that can also block the fibrillization 
process (Nilsson et al., 2004). 
The amyloid fibrils also shared similar structural morphologies and characteristic 
cross-β X-ray fiber diffraction pattern (Sunde et al.,1997). In the 1971 lysosomal 
extracts was discovered to digeste immunoglobulin light chain precursor protein into 
amyloidogenic fragments suggesting that many amyloid forming peptides were 
produced by the proteolytic processing of a precursor protein (Glenner et al., 
1971)GG, Terry W, Harada M, et al Amyloid fibril prpteins : proof of homology with 
immunoglobulin light chain by sequence analysis. Science 1971 ; 172 :1150-1).  
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 b 
                                                          
Fig 13 The misfolding protein is unable to adopt and remain in its native state (a) and it is converted 
from its soluble state into well organised fibrillar aggregates with amyloid-like characteristics (b) 
  
 
 
1.3.4 Structure of amyloid fibrils 
 
The studies on the charcterization of amyloid fibrils were carried out in the 1960s. 
The term «amyloid » was coined initially by Schleiden and then by Virchow in 
the1954 to describe the apparently tinctorial strach-like properties of the deposits. 
(Virchow et al., 1954). Further staining with the dye Congo Red was observed to 
produce a characteristic green birefringence when examined between cross-polarized 
light microscope  (in Fig 1.14) (Missmahl et al., 1953; Choen et al., 1965 ) suggesting 
that amyloids had fibrillar structure (Friedrich et al., 1859 ).  
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Fig 1.14 Isolated amyloid fibrils composed of Aα chain fragment of fibrinogen (a) stained with Congo 
Red and visualized by light microscopy and (b) between crossed polars, showing 
characteristicapple-green birefringence. Figure adapted from reference (amyloid fibrils Rambaran RN 
et al. Prion 2008) 
 
 
Subsequently electron microscope studies in the 1959 of amyloid demonstrated that a 
variety of amyloids had a similar morphology and ultrastructure consisting of uniform 
fibrils about 100 A wide, reported in Figure 15A (Choen et al., 1959) and combined 
with the observation of birefringence  with Congo Red suggested that the amyloid 
consist of linear structures arranged in an orderly and parallel fashion (Puchtler et al., 
1962). Further progress in biochemical and biophysical tecniques  allowed, in the 
1968,  the isolatation and purification of the amyloid fibrils from tissue, that stored 
the birefringent characteristic (Pras et al., 1968) and the fibrils subructure was 
confirmed using high-resolution electron microscopy ( Choen et al., 1965 ;  Glenner 
and Page, 1976). In the same years, the X-ray diffraction method, applied on isolated 
amyloid fibrils, produced diffraction patterns and showed that the fibrils were 
composed of polypeptide chains extended in cross-β-structure, reported in figure 15C 
(Eanes et al., 1969). The cross-β-structure were confirmed by NMR analysis 
(Lansbury et al., 1995). The initial work on the structural charatrization of amyloid 
fibrils established « ..that amyloid fibrils were defined by following overall structural 
features : (i) Straight, unbranched fibrils, about 100 A in diameter and indefinite 
lenght, which appear to be composed of two or more protofilaments, each 25-35 A in 
diameter. (ii) A molecular structure consisting of polypeptide chains in an extended β-
conformation, hydrogen-bonded together into sheets running parallel to the axis of the 
fibrils, with their constituent β-strands arranged perpendicular to this axis. (iii) A 
molecular structure that, whatever the origin of the amyloid fibril, is able to bind 
Congo Red and interact with the planar bis-diazo dye in such a way that the bound 
molecules are spatially ordered with respect to the fibrils in similar physicochemical 
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environments and therefore generate the characteristic green birefringence» (Sunde 
and Blake, 1997).  
The first complete X-ray diffraction analysis of fibrous protein with a cross-β 
structure was of the egg stalk of the lacewing Chrysopa by Geddes and co-workers in 
the 1968 (Geddes et al., 1968). The cross-β pattern of the amyloid fibrils has two 
characteristic signals, a sharp reflection at 4.7 Å along the same direction as the fibre 
and a more diffuse reflection at between 10 and 11 Å, related in Figure B, 
perpendicular to the fibre direction respectively arising from the hydrogen bonding 
distances between β-strands and side chain packing between the sheets, reported in 
Fig 1.15C (Makin and Serpell,  2005 ; Sunde et al., 1997; 273: 729-39 ; Makin et al., 
2006).   
 
 
                   
Figure 1.15. Synthetic amyloid fibrils made from Aβ peptide (A) electron micrograph showing long, 
straight, unbranching fibrils. (B) X-ray fiber diffraction pattern from partially aligned amyloid fibrils 
showing the characteristic “cross-β” diffraction pattern. (C) The structure of the Aβ amyloid fibril 
interpreted from ssNMR data,67 showing the top view of the fiber (i and ii) with side chains 
(i),showing the importance of side chain packing with in the fiber and as a cartoon (ii). The side 
view(iii) revealing the β-strands running perpendicular to the fiber axis. Figure adapted from reference 
(amyloid fibrils Rambaran RN et al. Prion 2008) 
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The pattern indicates that the fibrils have a particular core structure consisting of β-
sheet conformation in which the hydrogen bonding direction runs parallel to the fibre 
axis and the β-strands are perpendicular (Fig 1.15C) EM shows that the fibrils are 
straight, unbranching, 70-120 Å in diameter (showed in figure 1.15A) and are made 
up of individual subunit named « protofilaments ». (Cohen et al., 1982 ; Goldsbury et 
al., 1999; Kistler et al., 1999; Serpell et al.,  2000 ) Through cryo-electron microscopy 
and single particle processing of mature amyloid fibrils composed of SH3 domain of 
phosphotidylinositol-3`-kinase was discovered that a single fibril was comprised of 2–
6 unbranched protofilaments each 2–5 nm in diameter and associated laterally or 
twisted together to form fibrils with 4–13 nm (Jimenez et al., 1999). Subsequently, a 
molecular model of a SH3 amyloid fibril has been generated showing that each 
protofilament was composed of β-sheet structure and this model was confirmed by  
studies on synthetic amyloid fibrils from insulin (Jimenez et al., 2002) lysozyme 
(Jimenez et al., 2001) and Aβ (1-40) ( Sachse et al., 2006).  
 
                                                 
Figure 1.16 Models of mature protein fibrils based on Small-Angle X-rayscattering solution data. (A) 
Human alpha-synuclein fibrils and (B) humaninsulin fibrils.69 The results suggest that insulin fibrils 
(B) are formed of threeintertwining protofibrils, whereas α-synuclein fibril (A) consist of only 
oneprotofibril. Each protofibril is assumed to consist of two intertwining protofilaments.Four and three 
repeating units are shown for alpha-synuclein and insulin respectively. Figure adapted from reference 
(amyloid fibrils Rambaran RN et al. Prion 2008) 
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 The formation of amyloid fibrils has been shown not only to be associated with 
pathology but also with functionality in organisms from bacteria to humans. An 
increasing number of  proteins has been found to form fibrils in vitro with the same 
optical, morphologies and organizzation properties of the amyloid fibrils but without 
form protein deposits, reported in table 1.4. This finding has supported the idea that 
the ability to form the amyloid structure could be an inherent or generic property of 
polypeptide chains. This generic ability could be  required from the cells in specific 
conditions and purposes and  some organisms have been found to convert, during 
their normal physiological life cycle, one or more their proteins into amyloid fibrils to 
assolve specialized biological functions. (Stefani et al., 2003 ; Uversky et al., 1698). 
Curlin, a protein produced by Escherichia coli, is used by the bacterium to colonize 
inert surfaces and to mediate the binding to host protein. This protein is able to form 
fibrils with the same amyloid structure. The fibrils are 6-12 diameter and with 
extensive β-sheet structure (Chapman et al., 2002). A class of protein called chaplins 
able to form amyloid fibrils were identified in the hyphae producted by the 
filamentous bacterium Streptomyces coelicor (Claessen et al., 2003). 
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Table 1.4 Proteins forming naturally nonpathological amyloid-like fibrils with 
specific functional roles (Chiti-Dobson et al., 2006). 
Protein                         Organism                Function of the resulting  fibrils 
 
Curlin                                    E. coli                             To colonize inert surfaces and mediate              
                                              (bacterium)                      binding to host protein 
 
Chaplins                                S. coelicolor                    To lower the water surface tension  
                                               (bacterium)                     and the development of hyphae 
 
Hydrophobina EAS               Neurospora crassa           To lower the water surface tension  
                                                (fungus)                         and the development of hyphae 
 
 
Protein of the chorion of       Bombyx mori                 To protect the oocyte and developing 
eggshellb                                                 (silkworm)                      embryo 
 
Spidroin                                 Nephila edulis                To form the silk fibers of the web 
                                                (spider)          
 
Intralumenal domain of          Homo sapiens                To form, inside melanosomes, fibrous striations 
Pmel17                                                                          upon which melanine granules form 
 
Ure2p (prion)                          S. cerevisiae                   To promote the uptake of poor nitrogen sources 
                                                 (yeast) 
 
Sup35p (prion)                       S. cerevisiae                    To confer new phenotypes (PSI+) by  
                                                 (yeast)                            facilitating the readthrough of  stop codons 
 
Rnq1p (prion)                         S. cerevisiae                    Not well understood 
                                                 (yeast) 
 
HET-s (prion)                         Podospora anserina        To trigger a programmed cell death                     
                                                 (fungus)                           phenomenon (heterokaryon incompatibility) 
 
Neuron-specific isoform of     Aplisia californica         To promote long-term maintenance of synaptic 
CPEB (prion)                           (marine snail)                 changes associated with memory storage 
 
a Other proteins form this class, collectively called hydrophobins, have been found to play similar roles in other species of 
filamentous fungi. 
b Suggested to form amyloid-like fibrils in vivo, although amyloid formation has only been observed in vitro 
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1.3.5 Aggregation mechanism and fibrillogenesis of amyloid proteins 
in the neurodegenerative diseases 
The aggregation and accumulation of amyloid proteins or peptides in the CNS is 
considered to be fundamental to the initial development of neurodegenerative 
pathologies. Biophysical and biochemical studies combined with the generation of 
several mice transgenic models allowed the identification of the relationship between 
amyloid protein and the pathology and the association between amyloid aggregation 
and the development of the disease. Preliminary studies in vitro were very important 
to better understand the amyloid aggregation pathway and to identify the formation of 
different intermediates such as oligomers and protofibrils.  The model of fibrillization 
of amyloid proteins favored by most scientists is a nucleation-dependent 
polymerization mechanism, already studied for the process of crystallization of large 
and small molecules. This process is characterized by an initial lag-time phase 
(nucleation phase), followed by an exponential growth phase (polymerization phase) 
and a final plateau (equilibrium phase), reported in figure 1.17 (Harper et al., 1999; 
Stefani et al., 2003 ; Uversky et al., 2004).  
                   .   
Figure 1.17 Kinetic of amyloidogenesis  
 
The nucleation-dependent polymerization mechanism is characterized by (a) a slow 
nucleation phase, in which the protein undergoes a series of unfavorable association 
steps to form an ordered oligomeric nucleus, (b) a growth phase, in which the nucleus 
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rapidly grows to form larger polymers, and (c) a steady state phase, in which the 
ordered aggregate and the monomer appear to be at equilibrium (Figure 1.18). 
 
 
Fig. 1.18. Models of amyloidogenesis. (A) Nucleation-dependent fibrillation (Bhak et al. 2009) 
 
 
The characteristic features of a simple nucleation-dependent polymerization are as 
follows: (a) No aggregation occurs at a protein concentration below the critical 
concentration (Fig 1.19). (b) At protein concentrations that exceed the critical 
concentration by a small amount, there is a lag time before polymerization occurs. (c) 
During the lag time, addition of a seed results in immediate polymerization (Jarrett et 
al., 1993; Andreu et al., 1986; Harper et al., 1997). 
 
 
 
                                  
Figure 1.19 Fibril formation is concentration dependent. Below the critical concentration (CR) no fibril 
formation will occur. Above that concentration all added protein will be incorporated into the fibrils 
such that the monomer concentration never exceeds CR; this behavior is seen at equilibrum (Jarrett et 
al., 1993)  
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1.3.6 Aggregation toxicity in Alzheimer’s disease model 
 
A wide range of transgenic models allowed the capture of major features of 
neurological conditions and systemic amyloidoses. Many of these transgenic models 
successfully reproduce the Aβ plaques and the neurofibrillary tangles found in AD. 
Using transgenic mice models it is was possible to understand that there is an 
uncertain nature of the relationship between the deposits and the pathogenesis 
(Luheshi et al., 2009). Different studies showed that the Aβ plaques can be a poor 
indicator of cognitive decline in transgenic models (Oddo et al., 2003; Westerman et 
al., 2002), and this finding is consistent with neuropathological studies in humans ( 
Lue et al., 1999; Reiman et al., 2009).Therefore, the number and size of plaques in a 
postmortem AD brains do not correlate with the severity of symptoms at the time of 
the death and amyloid plaques are found throughout the cortex of many cognitively 
normal 70-year-old. (Dickson et al., 1992; Lansbury et al., 2006). Morever, recent 
clinical trial results suggest that removing the existing plaques from the brain may not 
reverse the cognitive decline (Holmes et al., 2008). The best explanation for these 
findings is that the intermediate species, pre-fibrillar aggregates and oligomers, 
formed during the amyloid aggregation pathway are likely to be primarily responsible 
for cell damage, (Fig 1.20). (Hass et al., 2007) . 
 
 
 
 
Figure 1.20 Amyloid aggregation mechanism; Aggregation of amyloid proteins, formation of 
intermediate toxic species and fibrils that were deposited in extracellular plaque such as in AD, or in 
intracellular inclusion such as PD. 
 
   33 
 
 Several studies have shown a correlation between soluble Aβ levels and the extent of 
synaptic loss and severity of cognitive impairment. The small oligomers can diffuse 
into synaptic clefts and may represent the better candidates to induce neuronal and 
synaptic dysfunctions. Several studies indicate that biochemically-measured levels of 
soluble Aβ, including soluble oligomers, correlate better than the presence of the 
plaques with the cognitive decline. (Lue et al., 1999; Wang et al., 1999).  
The large plaques of fibrillary Aβ in AD brain show surrounding dystrophic neurites, 
and the aggregates seem to be correlate with the neuronal injury. Probably the large, 
insoluble protein aggregates could not be directly involved in neuronal injury, but the 
protein aggregates are likely surrounded by a number of small and diffusible 
oligomers that might be responsive for neronal death and synapses loss. (Haas et al., 
2007) . 
 
 
1.3.7 Intermediates in the pathway of Aβ fibrillization and different 
types of Aβ oligomers 
 
Kinetic studies with different reporters and effect of different inhibitors of assembly 
suggest that a linear sequential process of fibrillar assembly is simplicistic. Inhibition 
of oligomeric formation but not fibril formation at low concentration of urea in vitro 
indicates that oligomers are not obligate in vitro precursor fibrils. (Levine et al., 
2007). 
Aβ assembly is a multistep process involving several transient intermediate species 
with different physical and biological properties, the intermediates species in the 
pathway of the Aβ aggregation are reported in Table 1.5.  
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Table 1.5  Intermediates in the pathway of Aβ fibrillization (Finder et al., 2007) 
 
Aβ species                   Characteristics 
Monomers                  soluble amphipathic molecule; generated from APP; potential α-helical,          
                                        random coil or β-sheet conformation 
Dimers                       intracellular localization in vivo, in human brain extracts and in vitro;     
                                       hydrophobic core; diameter of about 35nm 
 
Trimers                          observed in vivo in mouse models; potential key role as as subunit of toxic  
                                        oligomers 
Small Oligomers           observed in vivo in AD patients as well as in mouse models and in vitro; 
                                        heteromorphous; comprising of 3-50 monomers; mostrly transient, unstable    
                                        and toxic  
 
Anular Oligomers         observed in cell culture and in vitro experiments; potential role as membrane- 
                                        disrupting pores or ion channels 
 
 
ADDLs                           observed in murine and human brain extracts as well as in vitro; non fibrillar 
                                        neurotoxic; 17-42 kDa; trimers to 24mers 
 
Protofibrils                    observed in vitro; short, flexible; rod-like structure; maximum size 8×200nm 
                                        binding Congo red and thioflavine T; precursor of mature fibrils; toxic 
 
Fibrils                             observed in AD patients as well as in mouse moedels and in vitro; bind Congo    
                                  red and thioflavine T; stable, filamentous Aβ aggregates composed of  Aβ  
                                         units perpendicolar to the fiber axis 
 
Plaques                          observed in vivo AD patients as well as in mouse models; large extracellular 
                                       Aβ deposits; predominantly composed of fibrils; not toxic; surrounded by  
                                       distrophic dendrites, axons, activated microglia and reactive astrocytes 
 
 
Several intermediate aggregates have been described including protofibrils (PFs); The 
protofibrils were identified in the 1997 from Lansbury group and Teplow group; both 
groups reported that the Aβ42 peptide is able to form protofibrils more rapidly that the 
Aβ40 (Harper et al., 1997; Hartley et al., 1999; Walsh et al., 1997; Walsh et al., 
1999). Subsequently anular structures (Bitan et al.,2003; Lashuel et al., 2002), Aβ-
derived diffusible ligands (ADDLs) (Lambert et al., 1998; Gong et al., 2003), 
amylospheroids (Hoshi et al., 2003), Aβ56 (Lesne et al., 2006) and amyloid fibrils 
have been identified; the recognized Aβ oligomers are reported in table 1.6 (Haas et 
al., 2007).  
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Table 1.6 Oligomeric assemblies of Aβ (Haas et al., 2007) 
Oligomeric assembly             Characteristics 
Protofibril (PF)                               Intermediates of synthetic Aβ fibrillization; up to 150nm in length                
               5 nm in width; β-sheet structure: bind Congo red and Thioflavin T 
 
Anular assemblies                          Doughnut-like structures of synthetic Aβ; outer diameter of 8-12nm 
                                                                       Inner diameter of 2-2.5 nm 
 
Aβ-derived diffusible                      Synthetic Aβ oligomers maller then annuli: might affect neuronal  
Ligands (ADDLs)                            signal-tranductional pathways 
 
 
Aβ56                                                Apparent dodecamer of endogenous brain Aβ; detected in the             
                                                         brains of an APP transgenic mouse line and might correlate with 
                                                         memory loss 
 
Secreted soluble Aβ                        Produced by cultured cells; resistant to SDS; resistant to  
Dimers and trimers                         resistant to the Aβ-degrading protease IDE; alter synaptic structure 
                                                                     and  function 
 
 
 
 
 
1.3.8   Currently Theraphies in AD and PD 
Currently avaiable treatments for AD are the cholinoesterase inhibitors donepezil, 
rivastigmine and galantamine  cholinesterase inhibitors and N-methyl-aspartate 
(NMDA) antagonist memantine. These drugs offer primarily symptomatic benefits, 
providing temporary cognitive improvement and slowing disease progression. 
The characterization of the pathophysiology of the AD allowed the identification of 
new potential targets in the treatment of this disorder. Molecular, genetic, animal and 
clinical studies suggested that the production and accumulation of the β-amyloid 
peptide is fondamental to the initial development of neurodegenerative pathologhy 
and to trigger a cascade of the events that contribute to the progression of AD (Hardy 
et al., 2002 ; McLean et al., 1999). The oligomeric form of the Aβ peptide triggers a 
variety of secondary events such : tau hyperphosphorylation, synaptic degeneration, 
oxidative stress, excitotoxicity, inflammation and neuronal apoptosis (Salloway et al., 
2008).  
Current therapeutic strategies for treating PD treatment offer mainly transient 
symptomatic relief and aim at restoring the loss of dopamine by “dopamine 
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replacement therapy”. This is accomplished through the administration of levodopa 
(L-dopa), a direct precursor of DA and other drugs that increase the lifetime of DA by 
slowing its metabolism. Catechol-O-methyltransferase inhibitors (ICOMT), 
monoamine oxidase B inhibitors (IMAOB), dopamine receptor agonists and 
peripheral aromatic L-amino acid decarboxylase inhibitors (IADDC) are used as 
adjunctive medications to L-dopa used to slow DA degradation and increase the 
availability of brain DA (Sommer et al., 2008). 
The therapeutic approaches under investigation for the treatment of AD and PD 
consist in antiamyloid and neuroprotective therapies.  
 
 
1.3.9 Antiamyloid approaches in AD and PD 
 
The antiamyloid approach has as targets the inhibition of the amyloid aggregation 
mechanism.  
The targets of the antiamyloid approach in AD are the inhibition of the Aβ 
production, aggregation and accumulation in deposits and the clearance of the formed 
deposits. The antiamyloid treatments under active investigation in AD are reported in 
Fig 1.21.  
 
            
Figure 21 Amyloidogenic pathways in AD and sites for potential therapeutic intervention (Salloway et 
al. 2008) 
 
Treatments currently under investigation are the vaccination and immunization 
therapies. Inoculation of mice with an Aβ-derived immunogen resulted in the 
reduction of amyloid plaques. Transgenic mice with human APP mutation showed an 
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attenuation of AD after immunization with Aβ peptide (Schenk et al., 1999). Clinical 
trials were performed with synthetic Aβ peptide AN1792 in combination with an 
adjuvant, QS-21, on patients with moderate AD. First analysis on a small subset of 
patient with AD showed formation of antibody against Aβ peptide and slow cognitive 
decline. (Orgozono et al., 2003). At the same time a study with Aβ peptide AN1792 
was interrupted for the development of meningoencephalitis in a subset of immunized 
patients. (Hock et al., 2003). Currently several trials with passive immunization or 
vaccination with selective Aβ monoclonal antibodies are underway (Dodel et al., 
2004). 
A second antiamyloid strategy has as target the ihibition of secretases involved in the 
production of the Aβ peptide from APP, using β-secretase inhibitors, γ-secretase 
inhibitors, γ-secretase modulators. Several small molecules that inhibit the β-secretase 
and γ-secretase are under investigation. In vivo studies on APP transgenic mice the 
injection of a β-secretase inhibitor, KMI-429, into hippocampus reduced the Aβ 
production (Asai et al., 2006). Several inhibitors of γ-secretase as well as DAPT (El 
Mouedden et al., 2006) and LY450139 dihydrate (May et al., 2004) showed a 
reduction in Aβ levels in the brain, cerebrospinal fluid (CSF) and plasma. In a clinical 
trial with 70 patients with mild to moderate AD treated with LY450139 dihydrate for 
6 week the plasma Aβ levels were reduced but the CSF levels showed no significant 
change (Siemers et al., 2006). The treatment with γ-secretase inhibitors was well-
tollered and several studies are evaluating if high doses will have beneficial changes 
in Aβ levels without increase in toxicity.  
A third strategy in AD and PD involves the inhibition of the Aβ and α-syn 
aggregation and fibrillogenesis . Interestingly, small molecules such as Congo red, 
EGCG and Lac have recently been reported to affect fibril formation of several 
amyloidogenic protein including α-syn and Aβ peptide and to interact with 
monomeric unstructured protein (Masuda et al., 2006). The compound 3-amino-1-
propanesulfonic acid Tramiprasate, a sulfated glycosaminoglycan mimetic, is used to 
reduce of Aβ aggregation. This compounds reduces amyloid-plaque formation in 
mouse model and is well tolerated and can cross the blood-brain barrier (Gervais et 
al., 2006). Although many inhibitors of in vitro Aβ aggregation have been identified 
such as a small molecule inhibitor of in vitro fibrillogenesis, scyllo-cyclohexanehexol 
(AZD-103) that prevent and reverse Alzheimer phenotype in a mouse model 
(McLaurin et al., 2006 ). 
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Several factors could influence the balance between native amyloid protein, misfolded 
protein and the formation of the intermediates (oligomers, protofibrils, fibrils). 
Overproduction  or inappropiate post-translational modifications,  inhibition of the 
chaperone activity or of the protein degradation systems could induce the shift of the 
balance towards misfolded protein, oligomerization and fibril formation. Potential 
therapeuthical interventions on the amyloid aggregation pathway have been 
identified, reported in Fig 1.22 in blue. It is possible to block the formation of toxic 
species by upregulation of  the chaperones activity or by increasing of misfolded 
proteins degradation. The inibition of the misfolded protein aggregation at different 
steps on the amyloidogenic pathway could represent an alternative way to avoid the 
formation of the toxic species and the fibrillogenesis (Skovronsky et al., 2006). 
 
 
Figure 1.22 Amyloid aggregation pathway. Soluble native protein is misfolded and 
associates to form different intermediates 
 
However, the ability to block protein aggregation using small molecules provides 
unique opportunity to address the link between amyloid aggregation and toxicity by 
allowing the unlinking of these two processes. The is especially important in PD 
where the majority of affected patients do not carry mutations in the α-syn gene, 
mutations in several other genes are known to cause rare cases of early onset familial 
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PD. Initial efforts aimed at blocking or reversing protein aggregation focused on 
preventing amyloid formation or disruption of preformed fibrils as a mean of 
promoting their clearance. The accumulating evidence demonstrating that early 
intermediates on the aggregation pathway are the primary cytotoxic species, 
emphasize the importance of targeting the initial misfolding and/or aggregation steps 
on the amyloid formation pathway. Current therapeutic approaches to treat PD, 
related synucleinopathies  and AD are focused on slowing, blocking and/or reversing 
α-syn aggregation or Aβ aggregation and toxicity, include  1) reducing amyloid 
protein/peptide levels; 2) reducing and/or inhibiting amyloid protein/peptide 
oligomerization and fibrillogenesis; 3) promoting the clearance of amyloid 
protein/peptide aggregates; 4) preventing the formation of the toxic oligomers by 
diverting the aggregation pathway towards a non-toxic form of the protein or reducing 
their kinetic stability by accelerating/enhancing oligomer to fibril conversion.  
Several small molecules and short peptides have been reported as inhibitors or 
modulators of α-syn and Aβ fibrillization. These anti-fibrillogenic compounds belong 
to different classes like polyphenols and catecholamines ( Cappai et al., 2005;  Li et 
al., 2005; Conway et al., 2001; Norris et al., 2005; Zhu et al., 2004). Dopamine (D) 
and other catechols. Dopamine agonists and IMAO B, currently used as anti-
parkinsonian agents, have also shown to destabilize preformed fibrils (Li et al., 2007). 
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1.4 NEUROPROTECTIVE ROLE OF MICROGLIA AND 
POTENTIAL APPROACH APPROACH IN THE 
NEURODEGENERATIVE DISEASES 
 
1.4.1 Microglia cells distribution in the CNS and origin 
Microglia, the immune cells in the mammalian central nervous system (CNS), have 
been originally described by Rio-Hortega in the 1932.  
Microglia form approximately 10% of the brain (Kennedy et al, 1997). These cells are 
present in large number in all major division of the brain and they are an 
heterogeneous population in distribution and morphology. The density differs from 
5% in cortex and corpus callosum, to 12% in the substantia nigra. Particularly densely 
populated areas include the hippocampus, olfactory telencephalon, basal ganglia and 
substantia nigra (Lawson et al, 1990). 
Their origin is still a field of intense controversial discussion. The most accepted view 
assigns to microglia an exogenous mesodermal origin from bone marrow precursor 
cells that invade the central nervous system (CNS). (Navascuès et al, 1998; Stoll et al, 
1999; Chan et al, 2007). Their precursors of hemapoietic lineage enter in the nervous 
parenchyma from meninges, ventricular space and blood steam; the first brain 
colonization from microglial precursors occurs during fetal development and in early 
postnatal days. In these phases the microglial cells have properties of monocytes ( 
Navascués et al.,, 2000;  Hanisch et al., 2007). 
 
 
 
 
 
 
 
 
 
 
   41 
1.4.2 Neuron- microglia cross-talk in the development 
 
It has been demonstrated that the functioning of the CNS depends on a continuous 
inter-relationship between neuron and microglia (Schwab et al, 2004; Polazzi et al, 
2002; Aihara et al, 2000; Saab et al, 2008).  
These interactions consist in a “cross-talk” between the cells characterized by an 
exchange of molecular signals that starts in the development, continue in the adult 
brain and is enhanced in brain injury or in the microbe infections.  
The CNS controls the migration and the proliferation of microglial precursors by 
specific factors release from developing neurons  (Fig 1.23) (Navascues et al, 2000; 
Rock et al, 2004). Human fetal telencephalon can release signals like chemokine 
MCP-1, RANTES, IL-8 (Rezaie et al, 1997; Rezaie et al, 1999) and fractalkine 
(Harrison et al, 1998) or neuronal death that are able to recruit microglia in 
development (Rezaie et al, 2002). In the development, microglia interact with neurons 
at early stages of differentiation and secrete many neurotrophic factors implicated in 
all aspects of neuronal functions, neurogenesis and glial development (Hanischet et al, 
2002; Butovsky et al, 2006; Monje et al, 2003). These cells are also implicated in 
induction of apoptosis and synaptogenesis (Bessis et al, 2007).  One of primary 
function of the microglia during development is the removal of apoptotic neurons and 
the elimination of aberrant axons and entire denditric structures (Cullheim et al, 2007; 
Trapp et al, 2007; Rappert et al, 2004). In the retina has been demonstrated that nerve 
growth factor (NGF) of microglial source causes apoptotic elimination of retinal 
elemnets (Frade et al., 1998). 
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Figure 1.23 The maturation of neurons correspond to the acquisition of control functions on microglial 
cells. 
 
Microglia cells migrate in a stereotypical manner suggesting that migration is 
controlled by specific factors. Factors released during cell death may influence 
microglia migration, as several studies have reported the microglia precursors are 
attracted towards regions of the nervous parenchyma where intense cell death occurs 
(Pearson et al., 1993) 
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1.4.3 Neuron-microglia cross-talk in the adult brain 
 
Microglial cells have immune function; they are able to protect the CNS against 
microbe infections and injuries through phagocytosis, antigen presentation and 
cytokines secretion (Aloisi et al, 2001; Kreutzberg et al, 1996; Rock et al, 2004). 
In adult healthy brain the microglial cells are in a resting state characterized by 
ramified morphology (Hanisch et al, 2007). The ramification of microglia is 
accompanied with changes in cellular functions in the motility and in the partial loss 
of macrophagic functions characteristic of ameboid microglial precursors. The CNS 
exercise an endogenous control on the microglial state, through the release of secreted 
factors like neurotrophins and cytokines/chemiokines (Neurrmann et al, 1998; 
Harrison et al, 1998; Streit et al, 2001). 
Recently, it has been found that neurons produce several IgSF like CD200 (OX2 in 
rat), CD47 and CD22, chemokine like CX3CL1, neurotransmitters and neurotrophins 
like NGF, BDNF and NT-3 that keep microglia quiescent. It also has been found that 
the microglial cells express receptors that bound the respective factors (Biber et al, 
2006; Hoek et al, 2000; Farber et al, 2005; Biber et al, 2007), In mice CD200-/- the 
microglia form activated cell clusters characterized by a loss of ramifications, shorter 
glail process, increase of CD11b and CD45 expression (Hoeck et al, 2000).  
It has been demonstrated that neurons are able to block the production of 
inflammatory factors such as the release of nitric oxide and TNF-α by LPS 
simulation. The production of inflammatory factors after the LPS stimulation has 
been found high in mixed microglial cells and reduced in neuron-glia-coculture 
(Chang et al., 2000). 
Microglia respond to changes in microenvironment to help brain, after traumatic CNS 
injuries and microbe infections, with migration at the sites of damage (Heppner et al, 
1998) and activation. In the activated state, ramified microglia undergo a drastic 
change in cellular morphology, in cell size and they rapidly up-regulate the expression 
of a large number of cell surface molecules and secretory products like cytokines and 
growth factors. The microglia activation seem to have a double effect,neuroprotective 
and neurotoxic effect. It’s possible discriminate between a physiological activation 
that occurs in adult brain afterwards a neuronal damage and an hyperactivated state 
that occurs in aging and neurodegenerative disease in response to different factors 
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released from damaged neurons and and to the neuronal damage intensity. Damaged 
neurons release factors, such as ATP, IL-1, IL-6, TNF-alpha, TGF-beta, LIF, MCP-1 
CSFS, PAF, Glutamate and fractalkine that induce a physiological microglia 
activation. The physiological microglia activation induces the release of 
neuroprotective factors to repair the neuronal damage (Fig 1.26).  
 
 
1.4.4 Microglial activation in aging brain and neurodegenerative 
diseases 
 
In the adult brain the microglia is found in a ramified form that represent a quiescent 
condition of the microglia named “resting state” (Fig 1.24A). In the resting state the 
microglia have small bodies with several process and show a downregulation of the 
macrophagic characteristics. Microglia respond to changes in the microenvironment 
to help and maintain brain homeostasis. Following acute CNS injury microglia 
become activated and undergo phenotypical changes that include hypertrophy, an 
enhanced expression of immunological cell surface molecules, mitosis and changes in 
cytokines and growth factor production. Fully activated microglia retract their process 
and develop an enlarged cell body with the same shape of peripheral macrophages; 
the ameboid and reactive microglia have been found in pathological condition, with a 
rod-shape morphology and they are able to migrate to the site of injury (Fig 1.24B). In 
the activate state the microglia express on their surface molecules typical of the 
macrophage lineage, such as the major histocompatibility complex of class II (MCH 
II) (Streit et al 1999).  
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Figure 24 Morphology of microglial cells: A. Resting microglia. B. Ameboid microglia. C. Reactive 
microglia (intermediate stage). D. Specialize locations of microglia  in the adult brain: I. Neuronal 
satellite microglia. II. Glial satellite microglia, around astrocytes or oligodendrocytes. III. Perivascular 
microglia (Rezaie and Male, 1999). 
 
Microglial immunophenotype is highly dynamic and fluctuates with changing state of 
activation. Resting microglia express several surface molecules such as complement 
receptors (Graeber et al., 1988), Fc (Perry et al., 1985), macrophage specific antigen, 
CD4 (Perry et al., 1987) and leukocyte common antigen (LCA) (Akiyama et al., 
1990). After 24 hours of microglial activation the cells express molecules important 
for the interaction between lymphocytes and antigen-presenting cells such as 
upregulation of CR3 (OX-42) expression (Graeber et al., 1988), an increase of IgG-
immunoreactivity, thrombospondin and intercellular adhesion molecules (Kloss et al., 
1999; Moller et al., 1996). Changes occur in the expression of P2 purinoreceptors 
following LPS-induced activation probably in response to extracellular ATP, and the 
expression of major histocompatibility complex type I and type II, MCH I and MCH 
II (Streit et al., 2008) . 
Controversy remains concerning the effects of microglial activation on the CNS 
following brain injury. In vitro studies showed that highly reactive microglial cells 
produce neurotoxic factors which may be responsible for causing neurodegeneration. 
The microglia are able to release pro-inflammatory cytokines such as TNF-alpha, IL-
1, IL-6 and cytotoxic factors such as oxygen radicals, nitric oxide, glutamate (Fig 
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1.25). (Boje et al., 1992; Giulian et al.,, 1996). IL-1 and TNF-α have been shown to 
be involved in the development of CNS inflammation through the disruption of BBB, 
the induction of adhesion molecules and chemiokines from astrocytes and endothelial 
cells, which facilitate the infliltration of leukocytes into the CNS (Oh JW, Schwiebert 
LM, Benveniste EN Cytokine regulation of CC and CXC chemokine expression by 
human astrocytes J neurovirol (1999) 5: 82-94). On the contrary, in vivo experiments 
demonstrated that the microglial activation could be a neuroprotective process. (Streit 
et al., 2006; Moran et al.,  2004) . Activated microglia promote axonal regeneration in 
PNS (peripheral nervous system) and axonal regrowth in SNC (Lazarov-Spiegler et 
al, 1998). After six hours to transient middle cerebral artery occlusion (tMCAO) in 
the rats there was an increase of the TGF-β1 mRNA expression, an anti-inflammatory 
cytokines, released by microglia cells (Lehrmann et al, 1998). At the same time in 
vitro experiments showed that the microglia release anti-inflammatory cytokines 
TGF-β1, IL-10, IL-1 receptor antagonist (IL-1Ra) and neuroprotective factors such as 
fibroblast growth factor (bFGF), hepatocyte growth factor (HGF) and neurotrophins 
that could potentially rescue damaged neurons (Polazzi et al, 2002). 
Cytokines release by activated microglia varies temporally and quantitatively in 
different types of insult. Many microglial-derived cytokines could have a positive or 
negative effects on CNS and their neuroprotective or neurotoxic effect depends on the 
degree of microglial activation and severity of neuronal damage. In the spinal cord 
damage microglia rapidly upregulate the production of pro-inflammatory cytokines 
such as IL-1β, IL-6 and TNF-α, but in the regenerating facial nerve injury these 
cytokines are minimally elevated (Streit et al.,2008) . 
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Figure 1.25 Microglia activation and release of cytotoxic factors or neurotrophic factors 
 
Microglia undergo progressive activation in aged brain, suggesting that the control 
exerted by neuron is lost in parallel with aging-related impairment of neuronal 
function (Polazzi, 2002). The microglial age cause changes of the cytokines 
expression patterns and neuronal survival (Sawada ref63) and showed increased IL-1β 
immunoreactivity (Sheng et al., 1998). The treatment of neonatal mice with two 
microglial activators, 1-methyl-4phenyl1-1,2,3,6-tetrahydropyridine (MPTP) and 
lypopolysaccharide (LPS), showed  upregulation of IL-1β and IL-6 and neuronal 
recovery following initial MPTP-induced cell loss. In aged mice treated with MPTP 
showed significant neuronal loss. A similar situation was observed in microglial 
cultures obtain from cerebral cortex of aging rats replicated in vitro some 
phenotypical features characteristic of the activation state observed in vivo (Rozovsky 
et al., 1998). 
The lost of neuronal control on the microglial cells with the aging becomes much 
more dramatic in the presence of neurodegenerative diseases. The microglial cells 
were found activated in different neurodegenerative disease AD, PD, HIV and 
multiple sclerosis (MS). In AD an inflammatory response with the release of 
cytokines, protease, has been found associated with the presence of activated 
microglia at the level of the neuritic plaques (Cotter et al., 1999). In particular, has 
been proposed the neurotoxins released by activated microglia contribute to 
neurodegeneration in AD and this seems confirmed by the fact that the severity of 
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inflammatory response positively correlates with density of activated microglia in 
affected area (Carpenter et al., 1993).  
Microglial activation is primarily intended to protect neurons and is a component of 
the regenerative process. Recently studies hypothesized that microglial activation 
following neuronal injury, primarily constitutes a brain protective mechanism to limit 
neurodegeneration. (Minghetti et al., 1999). However, in several neuropathologies, 
where chronic inflammation is present, the inflammatory products derived from 
activated microglia may secondarily promote neurodegeneration and contribute to 
neuronal loss (Gonza´lez-Scarano and Baltuch 1999; Polazzi and Contestabile 2002; 
Streit et al. 2008). The interaction between neuron-microglia, the physiological 
activation after neurons damage and the hyperactivation state of the microglia in 
aging and neurodegenerative diseases are summarized in Fig 1.26. In this setting, the 
possibility to shift the balance of microglial cells from pro inflammatory to anti-
inflammatory states offers a good strategy to develop therapies for neurodegenerative 
diseases. The knowledge of the neuroprotective mechanisms of microglial cells, 
emerging from studies of in vitro neuron/microglia cross-talk, may help in identifying 
and targeting specific microglial-produced molecules that could account for neuronal 
survival. 
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Figure 1.26 Interaction between neuron and microglia in adult brain, in aging and 
neurodegenerative disease. 
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1.5 AIM OF THE THE  THESIS 
 
The aim of the present thesis was the identification of new neuroprotective 
therapeutical strategies in the PD and AD. First, we analysed the correletaion between 
the inhibition of amyloid aggregation and the neuroprotection in PD and AD. We 
identified inhibitors (two iCOMT and four polyphenols) of alpha-syn and beta-
amyloid aggregation, amyloid protein/peptide respectively involved in the PD and AD 
and afterwards we tested the neuroprotection of these amyloid inhibitors against 
alpha-syn and beta-amyloid-induced citotoxicity in PC12. Subsequently we focused 
on the study of the  neuroprotective role of microglia and on the possibility that the 
neuroprotection properties of these cells could be use as therapeutical strategy in PD 
and AD. We tested the neuroprotective role of microglia on PD-like 
neurodegeneration model (using 6-OHDA), AD-like neurodegeneration model (using 
AB42) and in the excitotoxicity (using Glutamate), involved in the major 
neurodegenerative diseases. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
EXPERIMENTAL PROCEDURES 
 
Thioflavin T, gallic acid, quercetin and MTT were purchased from Sigma-Aldrich. 
Dimethyl sulfoxide (DMSO) of microbiological quality,dopamine, caffeic acid and 
pyrogallol were from Fluka (Buchs, Switzerland). Entacapone and tolcapone were 
kindly donated by Prof. Alberto Gasco (Dipartimento della Scienza e tecnologia del 
Farmaco, University of Turin,Italy). DMEM, heat-inactivated horse serum,fetal 
bovine serum, gentamicin, insulin, NuPAGE 4-12% Bis- Tris gel, goat anti-
mouseAlexaFluor680 and SilverXpress SilverStaining Kit were from Invitrogen. 
Betaamyloid Monoclonal Antibody 6E10 was from Covance and nitrocellulose 
membranes from Protran. All chemicals were of analytical grade and all solutions 
were prepared in autoclaved distillate water. Compounds solutions were prepared in 
100 % DMSO (10 mM). Fresh solutions were prepared by diluting stock solutions in 
water to achieve a final amount of co-solvent less than 1%, in the reaction mixtures. 
 
2.1 Expression and purification of α-synuclein-Human wild type (WT)  
 
α-syn was expressed as previously described (Paleologou et al., 2008). Cells were 
harvested, resuspended in buffer and lysed. The supernatant was saved, concentrated 
and loaded onto a Superdex 200 size exclusion column. α-syn containing fractions 
were combined, lyophilized and stored at -20 °C until use. 
 
2.2 Preparation and characterization of Aβ42 low molecular weight (LMW) and 
protofibrils (PF) 
 
 Aβ42 was synthesized and purified by Dr. James I. Elliot at Yale University (New 
Haven, CT). Monomeric Aβ42 stock solutions were prepared by dissolving the 
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peptide in 6 M Guanidine-HCl at concentration of 1 mg/ml and centrifuged at 8,600 
rpm for 5 minutes. Low molecular weight (LMW) and protofibril (PF) Aβ42 stock 
solutions were prepared by dissolving the peptide in 5 % DMSO, 2 M Tris Base pH 
7.6. The mixture was subjected to low speed centrifugation at 6000 rpm for 5 minutes. 
The supernatant of Aβ42 monomeric, LMW and PF stock solutions was loaded onto a 
Gel filtration column (Superdex 75 HR 10/30 Amersham) previously equilibrated 
with 10 mM Tris buffer pH 7.4 (Jan et al, 2008). The fractions were analyzed by 
SDS-PAGE and protein concentration was determined by UV absorbance at 280 nm 
in 10-mm path-length cuvettes using the theoretical molar extinction coefficient at 
280 nm (1490 M-1 cm-1) (31). All Aβ42 stock solutions were diluted with Tris buffer 
pH 7.4 to a final peptide concentration of 10 µM. Samples of Aβ42 were incubated at 
37° C in 1.5 mL polypropylene sterile tubes, with and without different 
concentrations of inhibitors, at molar ratios of Aβ42: inhibitor of 1:0.5 and 1:2. 
 
2.3 Preparation of α-syn and Aβ42 seeds 
 
The seeds were prepared by incubation of 〈-syn peptide solution (20 mM Tris buffer, 
150 mM NaCl (pH 7.4)) and Aβ42 peptide solution (5% DMSO, 2 M Tris buffer (pH 
7.6) at 37°C under agitation for three days. The fibrils were then mechanically 
fragmented to yield narrow distribution of smaller fibrillar structures (100-300 nm 
long) by ultrasonication on ice using SONICS Vibra Cell TM equipped with a fine tip 
(20 x 5 second pulses, amplitude 40, output watts 6). The sonicated fibrils were 
diluted in 10 mM Tris buffer pH 7.4. Seeds and monomeric α-syn or Aβ42 were 
incubated for 4 hours at 37° C with continuous shaking, with and without inhibitors, 
in polystyrene black 384 well plates (Nunc,USA). 
 
2.4 Fibrilization Studies 
 
Purified, lyophilized α-syn was dissolved in 20 mM Tris buffer, 150 mM NaCl. The 
samples of α-syn at a concentration of 100 µM (as estimated by spectroscopy) were 
incubated at 37° C in 1.5 mL sterile polypropylene tubes, with continuous shaking, in 
the absence and presence of inhibitors, at a molar ratio of α-syn: inhibitors of 1:1, 
1:0.5, 1:0.1 and 1:0.01. Aliquots (10 µL) of the 〈-syn incubations (final protein 
concentration of 10 µM), previously incubated at 37° C with and without compounds, 
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were added to 80 µL of 50 µM Glycine-buffer (pH= 8.5) and 10 µL solution of 100 
µM Aliquots of 80 µL of 10 µM Aβ42 solutions (LMW or PF), previously incubated 
at 37° C in absence and in presence of compounds were added to 10 µL of 100 µM 
ThT and 10 µL of 50 µM Glycine-buffer (pH=8.5). The time course of α-syn and 
Aβ42 fibrillization was measured by ThT fluorescence assay. Fluorescence 
measurements were carried out with a spectrofluorometer (Analyst™ AD 96-384, 
Bucher Biotec AG, Basel) at 25° C using polystyrene black 384 well plates. The 
excitation wavelength was set to 450 nm and emission was monitored at 485 nm. All 
measurements were done in triplicates by performing three identical experiments. 
 
2.5 Seeding polymerization assay 
 
Polymerization of soluble α-syn with or without α-syn fibrils added as seeds and 
Aβ42 with or without Aβ42 seeds was assayed as described elsewhere (32). Nunc 384 
fluorescence plates were filled with monomeric and seed protein solutions. 
Compounds of interest (or Tris buffer containing DMSO 1% for the control) were 
finally added to the reaction mixture. The plate was incubated at 37°C for 3 hours 
under agitation. The kinetics and extent of fibrillization is monitored using the 
standard Thioflavin T (ThT) binding assay as described above. The assay was run in 
triplicate by processing three identical plates. 
 
2.6 Quantification of soluble α-syn and Aβ42 
 
SDS-page was performed to directly determine the amount of the monomeric α-syn 
and Aβ42 form after the incubation of the peptide (10µM) with the inhibitory 
compounds (20µM) at 37°C for 48h. Equal amount of protein samples were separated 
on NuPAGE 4-12% Bis-Tris gel and the electrophoresis was run at constant voltage 
of 130V. The gels were stained using the SilverXpress Staining Kit (Invitrogen), For 
western blotting analysis, the bands were transferred to a nitrocellulose membrane 
and blocked for 1h with the blocking solution (30% of Licor and 70% ofPBS). 
Subsequently the membranes were incubated with primary antibody, Betaamyloid 
Monoclonal Antibody 6E10 (1:5000), overnight at 4°C with agitation. The 
Nitrocellulose membranes were washed with PBS- Tween 0,1% and incubated with 
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the secondary Antibody, goat anti-mouse AlexaFluor680 (1:2000) for 1h at room 
temperature. Before to scan the membrane with Odyssey infared lector the 
membranes were washed with PBS-Tween 0,1% and PBS to remove the excess of 
antibody. 
 
2.7 Electron microscopy analysis of fibril formation 
 
Aβ and α-syn fibril formation was monitored by transmission electron microscopy 
(TEM). Samples for TEM analysis were prepared by placing 10 µL of the sample 
solution on formvar-carbon copper grid for 1 min before removing the excess 
solution. The grid was washed with two drops of distillated water and 1 drop of 
uranyl acetate before staining with 1 % of fresh uranyl acetate for 30 seconds. The 
grids were thoroughly examined to get an overall evaluation of the structures present 
in the sample. Specimens were inspected at 80 kV using a Philip CIME 12 electron 
microscope. Digitized photographs were recorded with a slow scan CCD camera 
(Gatan, Model 679). 
 
2.8 NMR spectroscopy 
 
NMR spectra were acquired on a Bruker Avance III 600 MHz NMR spectrometer at 
15°C. Measurements were performed using 60 µM 15N-labeled αS in 20mM Tris, 
150 mM NaCl pH 7.4. Two-dimensional 1H-15N Heteronuclear Single Quantum 
Coherence (HSQC) spectra were recorded using 256 × 1024 complex data points in 
the F1 and F2 dimensions, with a relaxation delay of 1.0 s (33). Sixty-four scans per 
increment were recorded for each spectrum. Spectral widths were 1612.9 and 7211.5 
Hz in the 15N and 1H dimensions, respectively. Spectra were processed with Topspin 
1.3 (Bruker Biospin) and NMRPipe (Goddand et al., 2003). Visualization and 
manipulation were performed using the public domain graphics program Sparky 3 
[Goddard TD, Kneller DG (2004) SPARKY 3. University of California, San 
Francisco]. Resonance assignments had been previously obtained (Delaglio et al., 
1995). The addition of 1% DMSO and a small change in temperature did not interfere 
with transfer of resonance assignment. 2D 1H-15N HSQC spectra were recorded to 
monitor chemical shift changes induced by the presence of three compounds (E,Q,T). 
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Compounds were freshly dissolved in DMSO to high concentration and added to the 
αS sample. The concentration of DMSO did not exceed 3% (v/v). Measurements were 
performed for molar ratios of 1:0.5, 1:2 and 1:10 αS:ligand. For each titration step, a 
reference spectrum was obtained by addition of the same amount of DMSO only. 
Both intensity and chemical shift differences were analyzed with respect to the 
DMSO reference spectrum. Mean weighted 1H-15N chemical shift differences were 
calculated according toΔav = {[(Δδ2HN + Δδ2N/25)]}/2 (Goddand et al., 2003; 
Delaglio et al., 1995; Grezesiek et al., 1996). 
 
2.9 PC12 preparation and toxicity studies 
 
The rat adrenal gland pheochrompcytoma cell line, PC12, were grown at 37°C in 5% 
of CO2 in DMEM supplemented with 6% heatinactivated horse serum, 6% of fetal 
bovine serum and Gentamicin 50µg/ml. Exponentially growing PC12 cells (5*104 
cells per well) were plated in 96-well tissue culture plates (Falcon) in a media 
supplemented with insulin 2µM and gentamicin 50µg/ml; the cells were co-treated 
with Aβ42 crude preparation (40µM) and the compounds (40µM) for 24h at 37°C and 
in 5% of CO2; the peptide and the compounds were added directly in the medium 
DMEM supplement with insulin 2µM and gentamicin 50µg/ml. The viability of PC12 
cells was evaluated by thiazolyl blue MTT (36) and luminescent cells assays. The 
MTT assay is based on conversion of tetrazolium salt to formazan (blue compound), a 
reaction that only occurs in viable cells since the chemical reaction is carried only by 
mithocondrial deidrogenases. MTT was added at final concentration of 0,5mg/ml for 
2h at 37°C and the crystal formed were dissolved using 100µl of solubilizzation 
buffer containing 30% SDS, 70% of the Isopropanol in water. The optical density was 
determined at 570 nm using a microplate reader. The luminescent cells viability assay 
is a sensitive method of determining the number of viable cells in culture based on 
quantitation of the ATP present, an indicator of metabolically active cells. The assay 
procedure involves adding the single reagent (Promega CellTiter-Glo® Reagent) 
directly to cells cultured. The light emission, measured by Safire Instrument, is 
directly proportional to the ATP produced. All quantitative data are presented as 
means +/- SE. Statistical analysis between different treatments was calculated by 
using one way analysis of variance (ANOVA) followed by post-hoc comparison 
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through Bonferroni's test. A value of p>0.05 was considered statistically significant. 
 
2.10 Microglial cell culture and microglial conditioned medium (MCM) 
preparation 
 
Microglial cells were prepared from cerebral cortex of newborn Wistar rats as 
previously described (Levi et al., 1993). Briefly, brain tissue was cleaned from 
meninges, trypsinized for 15 min and, after mechanical dissociation cell suspension 
was washed and plated on poly-L-lysine (Sigma, 10µg/ml) coated flasks (75 cm2). 
Mixed glial cells were cultured for 10-13 days in Basal Medium Eagle (BME, 
Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Invitrogen), 2 mM glutamine (Sigma) and 100 µM gentamicin sulphate (Sigma). 
Microglial cells were harvested from mixed glial cells cultures by mechanical 
shacking,  resuspended in serum free BME,  and plated on uncoated 40 mm dishes at 
a density of 1x106 cells/ml medium. Cells were allowed to adhere for 30 min and then 
washed to remove non-adhering cells. After 48 hours microglial conditioned medium 
(MCM) was collected, filtered through 0.22 µM filters, aliquoted  and stored at –20°C 
until used. To get insight into the nature and the range of molecular weight of the 
neuroprotective factor(s) present in MCM, some aliquots were boiled for 30 min 
before use. Other aliquots of MCM were treated with 1 µg/ml of proteinase k or 
peptidase (Sigma) for 1 hour at 37°C. Enzymatic activity was then killed heating the 
media at 95 °C for 10 minutes, a procedure that did not compromise the 
neuroprotective efficacy of MCM. Finally, other aliquots of  MCM were filtered 
using Microcon-YM-10 filters (Millipore). In this way, we obtained two different 
fractions for each type of medium: the fraction containing low molecular weight (<10 
kDa) substances and the one containing high molecular weight (>10 kDa) substances. 
The two fractions were separately resuspended in the original volume of medium to 
recreate a similar concentration of active factors, and used to test protection of 
neuronal cultures.  In some experiments, to evaluate the neuroprotective effect of 
TGF β-2, we have added 10 ng/ml of human recombinant TGF β-2 (Sigma) to the 
fraction of MCM <10kDa  that does not contain this cytokine. In another set of 
experiments we have also evaluated whether the neuroprotective effect of MCM was 
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inhibited when the signal transduction cascade of TGF-β2 was blocking by the 
compound SB 431542 (Inman et al., 2002). 
 
2.11 Cerebellar granule cell cultures  (CGC) 
 
Primary cultures of CGC were prepared from 7 day-old rats of Wistar strain as 
previously described (Gallo et al., 1987). Briefly, cells were dissociated from 
cerebella and plated on 40 mm dishes or in 24 well plates coated with 10µg/ml poly-
L-lysine at a density of 2x105 cells cm2 in BME supplemented with 10% heat-
inactivated FBS,  2mM glutamine, 100µM gentamicin sulphate and 25mM K+. After 
16 hours, 10µM cytosine arabino-furanoside (Sigma) was added to avoid glial 
proliferation. After 7 days in vitro (7div) differentiated neurons were shifted to serum 
free BME medium containing 25mM K+ and treated with different concentration of 6-
hydroxydopamine (6-OHDA, Sigma) in the presence or in the absence of MCM to 
test its neuroprotective effect. We have also tested the neuroprotective effect of 
<10kDa and >10 kDa fractions of MCM, MCM  previously heat-inactivated or MCM  
previously treated with proteinase K or peptidase (see above). All microglia 
conditioned media or their fractions, were added with KCl to reach a final 25mM K+ 
concentration. After 24 hours neuronal survival was analyzed through MTT test or 
nuclei count after Hoechst staining. Experiments were authorized by a local bioethical 
committee and were performed in accordance with the Italian and European 
Community law on the use of animals for experimental purposes.  
 
2.12 Western blot  
 
To analyze protein expression of insulin growth factor–I (IGF-I), brain derived 
neurotrophic factor (BDNF) and transforming growth factor β -2 (TGF β-2) in their 
mature or  precursor forms, on microglial cell cultures and on microglial conditioned 
medium, freshly detached microglial cells were plated in serum free BME  at the 
same density used to obtain microglial conditioned medium. After 2, 24 or 48 hours,  
microglial cell were collected directly in Loading buffer 2X (0.5 M Tris-HCl pH.6.8; 
4% SDS; 2% Glicerol; 0.2% Bromophenol Blue; 0.2M DTT). The cell from one well 
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(40 mm dish) were collected in 50 µl of Loading buffer 2X. Corresponding media 
were also collected and 1ml aliquots for every condition were lyophilized using 
Microcon-YM-3 (Millipore) and resuspended in 15 µl of Loading buffer 2X. Fifteen 
µl of each of  the two samples were loaded per lane onto a 15% polyacrilamide gel. 
After electrophoresis and nitrocellulose membrane transfer, the membranes were 
blocked for 1 hour  with 5% non-fat dried milk/0.1% Tween 20 in phosphate buffer, 
pH 7.4, and incubated overnight at 4°C with primary antibodies (rabbit polyclonal 
anti IGF-I, Santa Cruz Biotechnology, 1:1000; rabbit polyclonal anti BDNF, Santa 
Cruz Biotechnology, 1:1000, rabbit polyclonal anti TGF β 2, Santa Cruz 
Biotechnology, 1:1000). Subsequently, nitrocellulose membranes were incubated with 
a secondary antibody, a donkey anti-rabbit conjugated to horseradish peroxidase 
(1:2000, Santa Cruz Biotechnology), for 90 min at room temperature in 0.1% Tween 
20  phosphate buffer, pH 7.4. The labeled bands were visualized by enhanced 
chemiluminescence method (ECL, GE Helthcare).  The analysis of β-actin (Sigma) 
content, was performed to verify the amounts of proteins per lane.  
 
2.13 MTT assay 
 
The viability of CGC culture was evaluated by thiazolyl blue (MTT) assay (Hansen et 
al., 1989).  This method is based on the conversion of the tetrazolium salt to a colored 
compound, a reaction that only occurs in viable cells since the chemical reaction is 
carried on by mitochondrial dehydrogenases. MTT was added to the culture-medium 
to reach a final concentration of 0.1 mg/ml. Following 15 min of incubation at 37°C 
the dark crystals formed were dissolved in 0.1 M Tris-HCl buffer containing 5% 
Triton X-100 and the absorbance was read at 570 nm in a Multiplate 
Spectophotometric Reader (Biorad).  
 
2.14 Hoechst staining 
 
To quantify neuronal cell death, normal and condensed nuclei were counted after 
Hoechst stain. CGC were fixed for 20 min with 4% paraformaldehyde in phosphate 
buffer, washed in PBS and incubated for 5 min at room temperature with 0.1µg/ml 
Hoechst 33258. Cultures were observed and photographed with a fluorescence 
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microscope using a 20x objective and count was performed in 3 randomly selected 
fields of each dish. Quantitative evaluation of cell death was determined by 
calculating the percent ratio: condensed nuclei/condensed + normal nuclei  (Monti et 
al., 2001).  
 
2.15 Fluoresceine diacetate (FDA) staining and propidium iodide staining 
 
In experiments based on acute excitotoxic pulse of glutamate, living cells were 
stained with fluorescein diacetate (FDA) and nuclei of dead cells with propidium 
iodide (PI). Cells were washed with Locke’s solution, stained for 3 min at room 
temperature with the same solution containing15µg/ml FDA and 5µg/ml PI, washed, 
observed and photographed with the fluorescence microscope. 
 
2.16 Statistical analysis 
 
All quantitative data are presented as means ± SE from independent experiments. 
Statistical significance between different treatments, was calculated through one way 
analysis of variance (ANOVA) followed by post-hoc comparison through 
Bonferroni’s test. A value of p<0.05 was considered statistically significant. 
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CHAPTER 3 
 
RESULTS 
 
       3.1 PROTECTIVE EFFECT OF ANTIAMYLOIDOGENIC 
COMPOUNDS AGAINST α-SYN AND β-AMYLOID-induced 
CITOTOXICITY  
 
 
We evaluated the inhibitory potency of anti-Parkinsonian drugs and catecholamines 
towards the oligomerization, fibrillogenesis and toxicity of monomeric and 
oligomeric α-syn and Aβ42. These molecules include two nitrocatechols, i.e. 
Entacapone and Tolcapone (Bonifacio et al., 2007) approved as adjunct in the therapy 
of PD (scheme 3.1). These two coumpounds are Catechol‐O‐methyltransferase 
inhibitors, COMT inhibitors, used in the treatment of PD to block the oxidation of the 
levodopa, analogous of the dopamine.  
 
 
 
 
          Scheme 3.1 Working model illustrating that protein aggregation, i.e. α‑syn in PD and Aβ in AD, has a 
central role in the generation of the cascade of events that result in neurodegeneration and disease.  
 
 
Entacapone and Tolcapone have never been tested for their ability to modulate α-syn 
and Aβ42 aggregation and toxicity. These molecules were also investigated for their 
ability to inhibit and/or reverse the growth of α-syn and Aβ42 fibrils using a seeding 
polymerization assay. In addition, four natural polyphenols containing a catechols 
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moiety and which are known for their antioxidant properties, Quercetin, Caffeic acid, 
Gallic acid and an anti-inflammatory coumpound, Pyrogallol were tested as potential 
inhibitors of amyloid aggregation and inhibitors of the seeding polymerization. 
(Johnsonet al., 2005); Han et al, 2008; Dodo et al 2008; Armagan et al, 2008). The 
inhibitory potential of those compounds was compared to that of dopamine, a well-
known inhibitor of α-syn and amyloid-β fibrillization. The structures of the 
nitrocatechols and polyphenols are reported in table 3.1. Finally, we investigated the 
protective effects of these anti-amylogenic compounds against α-syn and Aβ-induced 
cellular toxicity on PC12. 
 
           
 
Table 3.1 Chemical structure of compounds examined as inhibitors of human WT α-syn and 
Aβ42 fibril formation. 
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3.1.1 Inhibition of α-syn fibrillization by Entacapone, Tolcapone and 
related catechols 
 
α-syn fibril formation is a concentration dependent process and occurs readily in vitro 
only under conditions that combine high protein concentrations (100-200 µM) and 
mechanical agitation to accelerate the process (Fig. 3.1).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1: α-syn fibril formation is a concentration-dependent process. Purified, lyohilized α-syn was 
dissolved in buffer 20 mM Tris, 150 mM NaCl pH 7.4. Samples α-syn were incubated at 37°C, with 
continuous shaking at 50 µM (a), 100 µM (b) and 200 µM (c). The time course of protein fibrillation 
was measured by ThT fluorescence assay after incubation for 48, 72 and 96h for the 50 µM sample and 
for 48 and 72 hours in the case of 100 µM and 200 µM samples. 
 
 
We evaluated the fibrillization of human WT α-syn alone under agitation in the range 
of 50-200 µM and a 100 µM protein concentration was chosen as the optimal 
concentration to assess the inhibitory activity of the compounds (Fig. 3.2). Under 
these conditions, α-syn fibrillization was complete after 72-96 hr of incubation at 37 
°C. To investigate the influence of the two nitrocatechols, entacapone (E) and 
Tolcapone (T), and the four natural compounds, quercetin (Q), caffeic acid (CA), 
gallic acid (GA) and pyrogallol (P) on α-syn aggregation, we monitored the 
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fibrillization of α-syn in the absence and presence of each compound in the 
concentration range of 1-100 µM using ThT fluorescence, SDS-PAGE analysis of 
soluble protein and TEM as a function of time. DA was chosen as a reference 
compound and was tested under the same working conditions. As shown in Fig. 3.2, 
after 72 hr of incubation, all compounds tested abolished α-syn fibril formation at 
concentrations of 50 and 100 µM. Compounds E, GA and Q exhibited strong 
inhibition of α-syn aggregation even at concentrations of 10 µM, with compound T 
demonstrating the greatest inhibition potency (Fig. 3.2A). More than 70-80% 
reduction of the ThT fluorescence signal was observed in all samples containing ≥ 10 
µM of compounds. The ThT results were confirmed by TEM, which demonstrated the 
absence of significant amounts of amyloid fibrils in α-syn samples incubated with the 
compounds at 100 µM concentrations (Fig. 3.2B). After 72 h, WT α-syn alone formed 
extensive fibrillar structures with an average diameter of 35 nm. In the samples 
containing 100 µM of E, T, Q, CA, GA and P, the number of fibrils was significantly 
reduced, and spherical oligomers and short sheared fibrils were observed instead. 
Aggregates formed in the presence of the various compounds were morphologically 
distinct from those formed by WT α-syn. To further confirm the inhibitory effect 
observed by ThT and TEM assays, we quantified the amount of remaining soluble 
protein by SDS-PAGE analysis of the supernatant after removal of fibrils and 
insoluble materials by centrifugation. The sample containing α-syn alone showed a 
reduction in band intensity corresponding to > ~ 70-80% loss of soluble α-syn after 72 
hr of incubation at 37 °C, suggesting that the majority of soluble α-syn has been 
converted into insoluble fibrils under these conditions. In contrast, all samples 
containing the compounds (100 µM) showed levels of soluble protein that correspond 
to the inhibitory effect reported by ThT and TEM. At 1:1 molar ratio, more than ~ 
60% of the starting protein remained in solution after 72 hr of incubation (Fig. 3.2A). 
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Fig. 3.2 The compounds abolish α-syn fibril formation and increase the soluble forms of α-syn 
after incubation for 72h. (A) Samples of 100 µM α-syn were incubated at 37 °C, with continuous 
shaking, with and without compounds, at molar ratios of α-syn: inhibitor of 1:0.1, 1:0.5 and 1:1. The 
time course of protein fibrillization was measured by ThT fluorescence assay after incubation for 72 hr. 
The bar graph represents the amount of fibril formation in absence and in presence of the compounds 
pyrogallol (P), gallic acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E), and 
dopamine (DA). The figure shows means of three independent experiments ± SD (n=6). The inhibitory 
effect of the compounds on α-syn aggregation was evalueted by SDS-PAGE. Samples of α-syn (100 
µM) were incubated with and without compounds, at molar ratios of α-syn:inhibitor of 1:1. The bands 
represent the amount of monomeric form of α-syn before incubation and after incubation for 72 hr in 
the absence and in the presence of the compounds. (B) Electron micrographs of negatively stained 
quaternary structures deposited from solutions of α-syn before incubation and after 72 hr incubation at 
37°C in the absence and in the presence of 100 µM compound. Scale bar represents 200 nm. 
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3.1.2 Inhibition of the seeding capacity of fibrillar α-syn 
 
The process of amyloid fibril formation follows a nucleation-dependent 
polymerization mechanism that is characterized by an initial lag-time phase 
(nucleation phase), followed by an exponential growth phase (polymerization phase) 
and a final plateau (equilibrium phase) (Harper et al., 1999) The spontaneous breakage 
of fibrils into smaller aggregates or their disassociation by small molecules or 
chaperones is believed to contribute to the spreading and acceleration of amyloid 
formation in vivo via a seeding mechanism (Grimminger-Marquardt et al., 2009).This 
is supported by in vitro and in vivo studies demonstrating that amyloid fibril 
formation is accelerated by the addition of preformed aggregates (Harper et al., Ann 
Rev Biochem 1997; Harper et al., Chem Biol 1997), which act as seeds that nucleate 
fibril formation and growth. In other words, the addition of seeds eliminates the lag 
phase associated with fibril formation. Therefore, blocking the seeding capacity of 
preformed fibrils is an attractive strategy for slowing amyloid formation and disease 
progression in PD and related disorders. For this purpose, the ability of the 
compounds to inhibit the seeding capacity of α-syn fibrils was investigated. To 
produce α-syn seeds, mature α-syn fibrils were mechanically disrupted by sonication 
to yield a narrow distribution of short fibrils. As expected, addition of small amounts 
of seeds abolished the lag phase and accelerated α-syn fibrillization (Fig. 3.3A). To 
determine the relative potency of the compounds towards blocking the seeding 
capacity of α-syn fibrils, 10 and 50 µM of each compound was added to a solution of 
freshly prepared monomeric α-syn. Fibrillar seeds at 2 µM final concentration were 
then added and the kinetics of fibrillization was monitored by ThT fluorescence. In 
the absence of compounds, fibrillization proceeds immediately to yield a dense 
network of amyloid fibrils. The fibrillization reaction was complete within 3 hr as 
opposed to 72-96 hr in the absence of the seeds. At 50 µM concentration of E, T, Q, 
P, and CA (full triangles in Fig. 3.3A) the seeding capacity of short α-syn fibrils was 
abolished by >90%. However, only Q and T exhibited a similar potency at lower 
concentrations (10 µM). The remaining compounds E, P, CA, GA, and DA still 
showed greater than 60-75% inhibition of seeded fibril growth at this concentration. 
These findings were confirmed by TEM, which demonstrated the presence of 
predominantly spherical structures and short isolated fibrillar assemblies, (Fig. 3.3B) 
in seeded samples containing 50 µM of the compounds compared to extensive fibril 
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formation in samples containing only α-syn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
Fig. 3.3 The compounds have an inhibitory effect on the α-syn seeding polymerization. (A) 
Samples of monomeric α-syn (100 µM) were incubated with the seeds (2 µM) at 37°C, with continuous 
shaking, without (a) and with (b-h) 10 µM and 50 µM of compounds pyrogallol (P), gallic acid (GA), 
caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E), and dopamine (DA). The time course 
of protein fibrillization was measured every 30 minutes by ThT fluorescence assay for 3 hr. (B) 
Electron micrographs of negatively stained quaternary structures deposited from solutions of seeds and 
α-syn+seeds after 3hr incubation in the absence and in the presence of the compounds (50 µM). Scale 
bar represents 200 nm. 
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Fig. 3.3 The compounds have an inhibitory effect on the α-syn seeding polymerization. (A) 
Samples of monomeric α-syn (100 µM) were incubated with the seeds (2 µM) at 37°C, with continuous 
shaking, without (a) and with (b-h) 10 µM and 50 µM of compounds pyrogallol (P), gallic acid (GA), 
caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E), and dopamine (DA). The time course 
of protein fibrillization was measured every 30 minutes by ThT fluorescence assay for 3 hr. (B) 
Electron micrographs of negatively stained quaternary structures deposited from solutions of seeds and 
α-syn+seeds after 3hr incubation in the absence and in the presence of the compounds (50 µM). Scale 
bar represents 200 nm 
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3.1.3 Entacapone (E), tolcapone (T) and related catechols do not bind 
to monomeric α-syn  
 
Binding of E, T and Q to monomeric α- syn was probed using nuclear magnetic 
resonance (NMR) spectroscopy. NMR signals of backbone amides constitute 
excellent probes of complex formation providing maps of interaction interfaces (Craik 
et al, 1997). We monitored the position and intensity of the NMR signals of α -syn in 
the presence of E, T and Q for molar ratios up to 1:10 α-syn:compound. In the case of 
Q, only a 1:2 ratio was reached due to its lower solubility. No significant chemical 
shift changes were observed for any of the compounds, with the exception of very 
minor chemical shift changes for His50 and some N-terminal residues (Fig. 
3.4A,B,C). As the very small chemical shift changes observed for His50 and the two 
to three N-terminal residues are most likely due to slight changes in pH, the NMR 
data suggest that there is no direct interaction of the compounds with the backbone of 
monomeric α-syn. Besides the position of NMR signals, their intensity is very 
sensitive to changes in the conformational properties of a protein as well as its 
chemical environment. For example, signal broadening indicates increased chemical 
exchange. When we compared the intensity of NMR signals in 2D 1H-15N HSQC 
spectra of α-syn in the free state and in the presence of the compounds E and T, 
residues in the C-terminal domain showed a different response than those of residues 
20-105 (Fig. 3.4D, E, F). NMR signal intensities in the C-terminal domain in the 
presence of E and T were within 10-15% of the values in the free state. In contrast, a 
large number of residues in the N-terminal domain of α-syn, in particular in the NAC 
region showed an increase of up to 30% in NMR signal intensity in the presence of E 
and T when compared to the DMSO control spectrum. The increased NMR signal 
intensities point to an increase in the backbone flexibility of these residues or to a 
reduced amide proton exchange. Interestingly, a similar increase in NMR signal 
intensities was observed for residues 22-93 of α-syn in the presence of polyamines, 
which bind to the C-terminus of monomeric α-syn (Fernández et al., 2004). 
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Fig. 3.4 Analysis of compound binding to monomeric α-syn by NMR spectroscopy. Changes in 
individual cross-peak positions (panels A, B, C) and intensities (panels D, E, F) of backbone 15N-1H 
resonances of α-syn (60 µM) in 2D 1H-15N HSQC spectra in the presence of compound E (panels A 
and D), T (panels B and E) and Q (panels C and F). For compounds E and F, molar ratios of 1:10 α-
syn:compound were used. Compound Q is less soluble and only the 1:2 α-syn:compound ratio could be 
measured. Horizontal lines indicate the average variation of chemical shifts observed for α-syn from 
sample to sample due to slightly different buffer conditions. 
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3.1.4 All compounds protect PC12 against α-syn induced cell death 
 
To investigate the effect of the E and T and related compounds in Fig.1 against α-
syninduced extracellular toxicity on the PC12 cells, we used a preparation of α-syn 
which was incubated in the presence and/or absence of compounds for 72 °C at 37 °C 
under agitating conditions. The α-syn-compound mixtures were then added to the cell 
culture media and cell viability was evaluated using the MTT assay. The treatment 
with the preaggregated α-syn (40 µM) showed a reduction of cellular viability by ~ 40 
% (Fig. 3.5). α-Syn samples which were incubated with inhibitors showed a 
significant increase of cell viability in the range of 10-30%. Interestingly, E was 
found to be the most active compound, with a protective effect close to 100%. These 
results suggest a direct correlation between the effect of these compounds on the 
fibrillization of α- syn and protection against α-syn-induced extracellular toxicity, 
which may be linked to the compounds ability to block the formation of the toxic 
entity or processes. 
 
                          
 
 
 
 
 
 
 
 
 
 
 
    
 
Fig. 3.5 Protective effect of the compounds against α-syn induced toxicity in PC12 cells. PC12 
cells were treated with pre-incubated α-syn (40µM) alone or co-incubated with 5µM of gallic acid 
(GA), caffeic acid (CA), quercetin (Q), tolcapone (T) and entacapone (E) and 40µM of pyrogallol (P) 
and dopamine (D). The cellular viability was evaluated by MTT assay and the data were expressed as 
percentage of the control (non treated cells). The control treatment is set to 100%. Bars are means ± 
S.E. We used # to compare the data to the control and * respect to the treatments with α-syn. A:## p< 
0.001, B:*** p< 0.001, C:**p< 0.01, D:*p< 0.05. 
Control !-syn 40!M  5!M  
!-syn  +  
DA 
+  
CA  
+  
E  
+  
GA  
+  
P  
+  
T  
+  
Q  
C
el
l 
v
ia
b
il
it
y
 (
%
 o
f 
co
n
tr
o
l)
 
## 
** 
 * 
*** 
*** 
   72 
3.1.5 Entacapone (E), tolcapone (T) and related catechols inhibit the 
conversion of low molecular weight (LMW) Aβ42 into fibrils 
 
In order to assess the inhibitory specificity of the compounds towards α-syn 
fibrillation, we investigated their capacity to inhibit the fibrillization of monomeric 
(LMW) and protofibrillar (PF) Aβ42, which were prepared freshly by size exclusion 
chromatography (SEC) as described previously (Jan et al, 2008). Fresh monomeric 
Aβ42 solutions were incubated (37°C), with and without compounds at molar ratios 
compound: Aβ42 of 0.5:1 and 2:1 for 24 hr and 48 hr. In the presence of 5 µM (data 
not shown) and 20 µM of compounds (Fig. 3.6A), Aβ42 fibrillization was decreased 
by ≥ 50% after 48 hr of incubation. Q was found to be the most potent compound, 
showing greater than 80% inhibition of Aβ42 fibrillization at 5- 20 µM, whereas the 
remaining compounds showed inhibition in the range of 60-70% at higher molar 
ratios (2:1, compound: Aβ42). These findings indicated that these compounds act by 
one of the following mechanisms: 1) by stabilizing monomeric Aβ; 2) by kinetic 
stabilization aggregation intermediates that precede mature fibril formation; or 3) by 
altering the aggregation properties of Aβ42 such that ThT negative large aggregates 
are formed. To determine their mode of action, the samples were analyzed by electron 
microscopy. TEM images of LMW Aβ42 following incubation for 48 hr in the 
presence of compounds indicate E and T stabilize distinct aggregate morphologies 
compared with the other compounds (Fig. 6B). Negatively stained TEM images of 
LMW alone revealed amyloid fibrils (diameter of 30nm) in the sample after 48 hr 
incubation (Fig. 3.6B). Aβ42 solutions containing 20 µM of E and T revealed 
predominantly large networks of PF-like tructures and the absence of mature fibrils. 
In comparison with E and T, the other compounds P, GA, CA and DA appeared to 
exert different effect on Aβ fibrillization. GA and CA were shown to stabilize smaller 
PF structures and result in the formation network of amorphous aggregates, after 48hr 
incubation at 37 °C. When Q was added to the sample containing Aβ42 LMW, we 
observed the formation of predominantly LMW and PF species. 
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Fig. 3.6 The compounds inhibit low molecular weight (LMW) Aβ42 fibril formation. (A) Samples 
of LMW Aβ42 were incubated at 37°C with and without compounds, at molar ratios of Aβ42: inhibitor 
of 1:2. The time course of protein fibrillization was measured by ThT fluorescence assay. The bar 
graph represents the amount of fibril formation in absence and in presence of the compounds 
pyrogallol (P), gallic acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E), and 
dopamine (DA). The samples containing the compounds showed a decrease of the ThT fluorescence 
signal after 48 hr incubation. The figure shows means of three independent experiments ± SD (n=6). 
(B) Electron micrographs of negatively stained quaternary structures deposited from solutions of LMW 
Aβ42 (10 µM) before and after 48 hr incubation at 37 °C in the absence and in the presence of 20 µM 
of the compounds listed. Scale bar represents 200 nm. 
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3.1.6 Entacapone (E), tolcapone (T) and related catechols inhibit the 
conversion of Aβ42 protofibrils (PF) into mature fibrils in a specific 
and concentration dependent manner 
 
To test our hypothesis and determine if these compounds act by targeting 
intermediates on the amyloid pathway, we evaluated their capacity to block the 
conversion of PFs into mature amyloid fibrils. PFs are metastable oligomeric 
intermediates, which have been observed during the in vitro fibrillization of Aβ and 
almost all other amyloidogenic proteins (Lansbury et al., 2006). During the last 
decade, mounting evidence from in vivo and in vitro studies point toward early 
aggregation intermediates, including PFs, as the major cytotoxic species responsible 
for triggering neurodegeneration in AD, PD, prion diseases and other related diseases 
(Caughey et al., 2003). Freshly isolated PFs were co-incubated with 5 and 20 µM of 
compounds and the aggregation was monitored by ThT fluorescence and TEM after 
24 hr (data not shown) and 48 hr at 37 °C. After 48 hr, the samples containing PFs 
alone showed an increase in ThT signal consistent with a conversion of the PFs into 
mature fibrils (Fig. 3.7A). When PFs were incubated with 20 µM GA and CA the 
increase in ThT fluorescence observed with PFs alone was reduced by approximately 
50%. More than 70% reduction in the ThT signal was observed in the samples 
containing 20 µM of P, E and DA suggesting that these compounds are more effective 
at inhibiting the PF to fibril conversion. However, co-incubation of PF with 20 µM of 
Q or T resulted in > 80-90 % inhibition, with Q being the most potent inhibitor of PF 
growth and fibrillization in the series. As expected, TEM analysis of the samples 
containing PFs alone after 48 hr of aggregation showed dense networks of fibrils. In 
the presence of Q, T, E, DA, mainly PF-like structures, similar to those present at the 
starting conditions were observed, in addition to only some isolated short fibrils (Fig. 
3.7B). Short fibrils were observed in the presence of GA and CA after 48 hr (Fig. 
3.7B), which is consistent with the higher ThT signal in these samples (Fig. 3.7A). 
 
 
 
 
 
   75 
            A                 
 
 
 
 
 
 
 
 
 
Fig. 3.7 The compounds prevent the conversion of Aβ42 protofibrils (PF) into mature fibrils in a 
specific and concentration-dependent manner. (A) Samples of PF Aβ42 stock solutions were 
prepared by dissolving the peptide in 5 % DMSO, 2 M Tris Base pH 7.6. Samples of Aβ42 were 
incubated at 37 °C with and without compounds, at molar ratios of Aβ42: inhibitor of 1:2. The time 
course of protein fibrillization was measured by ThT fluorescence assay. The bar graph represents the 
amount of fibril formation in absence and in presence of the compounds pyrogallol (P), gallic acid 
(GA), caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E) and dopamine (DA). The 
samples containing the compounds showed a decrease of the ThT fluorescence signal after 48 hr 
incubation. The figure shows means of three independent experiments ± SD (n=6). (B) Electron 
micrographs of negatively stained quaternary structures deposited from solutions of PF Aβ42 (10 µM) 
before incubation and after 48 hr incubation at 37 °C in the absence and in the presence of 20 µM of 
the compounds listed. Scale bar represents 200 nm. 
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3.1.7 Only Entacapone (E), Tolcapone (T) are effective in inhibiting the seeding 
capacity of Aβ42 
 
To determine if E, T and related compounds can block Aβ42 aggregation at a later 
stage of the fibrillization process, i.e. fibril growth, the capacity of the compounds to 
interfere with fibril elongation and the seeding capacity of Aβ42 fibrils was evaluated 
using the seeding polymerization assay described above. Fibrillar seeds of Aβ42 were 
prepared by fragmenting preformed and purified fibrils by sonication. The freshly 
prepared fibril seeds were added to a fresh monomeric solution of Aβ42 and co-
incubated with each of the compounds (20 µΜ). The kinetics of fibrillization was 
followed over a period of 3 hr with ThT and the structures of the final aggregates 
were characterized by TEM. Among all the compounds, only E, T and Q showed 
significant reduction in fibril growth and inhibition of the seeding capacity by Aβ42 
fragmented fibrils (Fig. 3.8). Analysis of these samples by TEM revealed 
predominantly short fibrillar structures resembling the fibrillar seeds, consistent with 
the ThT results (data not shown). These results further confirm that these E, T and Q 
interfere with the elongation and growth of Aβ42 fibrils possibly via direct 
interactions with either Aβ42 seeds or monomers or both. After 3 hr incubation, no 
inhibition was observed in the samples containing P and CA. Moreover, addition of 
GA and DA to the mixtures containing Aβ42 monomers and seeds did not affect the 
rate of fibrillization and resulted in only slight reduction of the ThT fluorescence 
signal (Fig. 3.8). 
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Fig. 3.8 The Aβ42 monomeric seeding polymerization assays revealed that Q, E and T have an 
inhibitory effect on the kinetic. Samples of monomeric Aβ42 (10 µM) were incubated with the seeds 
(2 µM) at 37 °C, with continuous shaking, without (A) and with (B-H) 20 µM of compounds pyrogallol 
(P), gallic acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E), and dopamine 
(DA). The time course of protein fibrillization was measured every 30 minutes by ThT fluorescence 
assay for 3 hours. 
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3.1.8 Protection against Aβ42-induced toxicity in PC12 cells  
 
Previous studies reported that natural polyphenols like Q, GA and CA are 
neuroprotective against Aβ toxicity. The effects of Q and GA have been studied 
against Αβ42 in primary cultures (Ansari et al., 2009; Ban et al, 2008; Bastianetto et 
al., 2006) and in vivo models of AD (Ehrnhoefer et al., 2008). Recently, the protective 
role of CA on Aβ-induced toxicity in PC12 cells was also described (Sul et al., 2009). 
We sought to determine if there is a correlation between the inhibitory potency of the 
polyphenolic compounds on Aβ aggregation and their effect on Aβ-induced toxicity 
in PC12 cells. The compounds were pre-incubated at concentrations in the range of 5 
- 40 µΜ with crude preparation of Αβ42, i.e. preparations containing predominantly 
LMW and PF Αβ42. These conditions were chosen to mimic the pathological 
situation in vivo where both the LMW and PF species are populated in the diseased 
AD brain. After incubation with Aβ 42 for 20 - 30 min, the Aβ –compound mixtures 
were then added to PC12 in cell culture media. The cellular viability was assessed 
after 24 hr using MTT and luminescent assays (Jan et al, 2008). All the compounds 
tested did not increase the mortality of PC12 cells in the absence of Aβ42 even at the 
highest concentration of inhibitors (40 µM, see Fig.3.9), demonstrating that the 
compounds do not enhance cell viability on their own over a concentration range of 
10 – 40 µM. The cells were then treated for 24 hr either with 40 µM of Αβ42 alone or 
in the presence of 5 µM, 10 µM, 20 µM and 40 µM of the compounds (Fig. 3.9).  
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Figure 3.9 Concentration-dependent effects of the compounds on Aβ42-induced toxicity in PC12. 
The cells were treated with different concentration of compounds alone (5µM, 10µM, 20µM, 40µM) or 
co-treated with Ab42 (40µM) in presence of the compounds Pyrogallol (A), Gallic acid (B), Caffeic 
acid (C), Quercetin (D), Entacapone (E), Tolcapone (F) and Dopamine (G) for 24h at 37 °C. The 
cellular viability was evaluated by MTT assay and the data were expressed as percentage of control, 
the control treatment is set to 100%. Bars are means ± S.E. 
 
Exposure of PC12 cells to 40µM of Aβ42 reduced the cellular viability by 
approximately 40% and 50% (Fig. 3.10 and 3.11) as determined by the MTT assay 
and ATP release, respectively (Fig. 3.11) with respect to the control (untreated cells). 
At higher concentrations of polyphenols (20 µM and 40 µM) were found to be 
protective against the Aβ42 toxicity but the attenuation of the toxicity was less 
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evident when compared to the effect observed at low concentration. However, P and 
DA showed a strong protective effect at a concentration of 40 µM. At low 
concentration (5 µM) E and T induced a significantly (~ 30%) protection against Aβ-
induced toxicity whereas at higher concentration (10 µM, 20 µM and 40 µM) we 
found an increase of cellular viability and ATP release of approximately 20 %. These 
observations indicate that the protection in the co-treatment of the PC12 cells could be 
related to a dual activity of the compounds, i.e. their inhibitory activity against Aβ 
aggregation and protection against Aβ-induced cell toxicity. 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10 Protective effect of the compounds against Aβ42–induced toxicity in PC12 cells. PC12 
cells were treated with Aβ42 (40µM) or co-treated in presence of the compounds pyrogallol (P), gallic 
acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E) and dopamine (D). The cells 
were treated with two different compound concentrations: 5 µM and 20 µM for 24 h. The cellular 
viability was evaluated by MTT assay and the data were expressed as percentage of control (non 
treated cells). The control treatment is set to 100%. Error bars are means ±S.E. We used # to compare 
the data to the control and * respect to the treatments with Aβ42 crude preparation. A: ### p<0.001, B: 
*** p<0.001, C: **p<0.01, D: *p<0.05. The statistical value was ### for the treatment with Aβ42 
crude preparation respect to the control; the statistical values for the compounds were ***p<0.001 for 
GA (5 µM and 20 µM), CA, Q, E (5 µM), and **p<0.01 for P (5 µM and 20µM), T (5 µM and 20µM), 
CA, Q, E and D (20 µM). 
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Fig. 3.11 Protective effect of the compounds against Aβ42–induced toxicity in PC12 cells. PC12 
cells were treated with Aβ42 (40µM) or co-treated in presence of the compounds pyrogallol (P), gallic 
acid (GA), caffeic acid (CA), quercetin (Q), tolcapone (T), entacapone (E) and dopamine (D). The cells 
were treated with two different compound concentrations: 20 µM and 40 µM for 24 h. The cellular 
viability was evaluated by ATP luminescence assay and the data were expressed as percentage of 
control (non treated cells). The control treatment is set to 100%. Error bars are means ±S.E. We used # 
to compare the data to the control and * respect to the treatments with Aβ42 crude preparation. A: ### 
p<0.001, B: *** p<0.001, C: **p<0.01, D: *p<0.05. The statistical value was ### for the treatment 
with Aβ42 crude preparation respect to the control; the statistical values for the compounds were 
***p<0.001 for GA (5 µM and 20 µM), CA, Q, E (5 µM), and **p<0.01 for P (5 µM and 20µM), T (5 
µM and 20µM), CA, Q, E and D (20 µM). 
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NEUROPROTECTION OF MICROGLIA IN PD AND AD 
DEGENERATION MODELS 
 
In recent years, our laboratory and others have performed in vitro studies based on co-
culture of neurons and microglia or on the use of conditioned media to elucidate the 
neuroprotective functions of microglial cells (Toku et al, 1998; Zietlow et al, 1999; 
Park et al, 2001; Polazzi et al, 2001; Figueiredo et al, 2008; Lai and Todd, 2008). In 
particular, it has been demonstrated that microglia conditioned media prevent 
apoptosis of cerebellar granule neurons (CGNs) induced by shift to low potassium 
and that diffusible signals from apoptotic neurons increase microglial neuroprotective 
action (Polazzi et al., 2001). In this setting, the possibility to shift the balance of 
microglial cells from pro inflammatory to anti-inflammatory states offers a good 
strategy to develop therapies for neurodegenerative diseases. We investigated the 
neuroprotection of microglia in vitro models of Parkinson-like neurodegeneration, 
Alzheimer-like neurodegeneration and excitotoxicity induced by exogenous glutamate 
on cerebellar granule neurons (CGNs). 
In the present study we have extended our in vitro ‘microglial neuroprotective model’ 
to an in vitro model of Parkinson-like neurodegeneration, i.e. 6-hydroxydopamine (6-
OHDA)-induced death in CGNs, a widely used model to study mechanisms of 
neuronal survival/death (Contestabile et al, 2002). The neurotoxin 6-OHDA has been 
shown to induce CGNs death through production of free radicals, alteration of protein 
degradation mechanisms and accumulation of ubiquitinated proteins (Dodel et al., 
1999; Lin et al., 2003; Chen et al., 2004; Ma et al., 2006; Monti et al., 2007), all 
typical features of the Parkinson’s Disease (PD)-like death caused by the toxin on its 
specific target represented by dopaminergic neurons of the substantia nigra (reviewed 
by Blum et al., 2001; Bove´ et al., 2005; Olanow et al., 2007).  
Subsequently, the neuroprotective effect of the microglia conditioned media was 
evaluated in a AD-like neurodegenerative models caused by Aβ42-induced 
cytotoxicity on CGNs. 
We have used our in vitro ‘microglial neuroprotective model’ against apoptotic death 
of CGNs caused by staurosporine, and against a mild excitotoxic stimulus delivered 
through sub-chronic glutamate treatment and against a stronger and acute excitotoxic 
insult.  In the excitotoxicity a non-physiologic increase of the glutamate in the 
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presynaptic region induces the iperstimulation of the glutamate receptors 
(metabotropic and ionotropic receptors). The iperactivation of both receptors induce 
an increase of intracytoplasmic calcium  that is an apoptotic stimulus for the cell. The 
excitotoxicity represents a mechanism common to the major neurodegenerative 
diseases and the regulation of glutamate extracellular levels and glutamate-induced 
toxicity could be a potential therapeutical approach in many neurodegenerative 
disease such as: PD, AD, HD, amyotrophic lateral sclerosis (ASL). 
Finally, we tried to identified the protective factor/s released as soluble factors present 
in the microglia conditioned medium in response to 6-OHDA toxin. 
  
 
 
 
3.2.1 Neuroprotection of Microglial condition medium 48hours 
(MCM48h) against 6-OHDA in cultures of rat cerebellar granule 
neurons (CGNs) 
 
 
In agreement with previous results (Dodel et al. 1999; Monti et al. 2007), cultures of 
fully differentiated CGNs at 7 days in vitro are dose-dependently sensible to the 
neurotoxic insult caused by 24-h exposure to 6-OHDA, based on the MTT assay and 
on nuclei count following Hoechst staining (Fig. 3.12). Exposure of CGNs to 6-
OHDA in presence of medium previously conditioned for 48 h by cultured microglial 
cells (microglia conditioned medium, MCM) resulted in nearly complete preservation 
of cell viability, evaluated through MTT assay, even at the most toxic 6-OHDA 
concentrations (Fig. 3.10a). Any in vivo toxin hitting neurons would likely also affect 
microglia. In order to gain better insight into the functional significance of the 
neuroprotection granted by MCM, we verified whether the MCM neuroprotective 
effect was maintained following exposure of microglia to 6-OHDA. While a toxic 
effect towards microglia was exerted by 6-OHDA at high concentration (data not 
shown), the medium conditioned by microglia exposed to 20 lmol/L 6-OHDA for 48 
hours protected CGNs, challenged with 6-OHDA themselves, similarly to the normal 
MCM (Fig. 3.12b). To obtain a more precise assessment of cell death caused by 6-
OHDA and of the extent of the MCM neuroprotection, we counted the condensed and 
normal nuclei in randomly selected fields of cultures stained with Hoechst (Fig. 
3.12c). The quantification of the condensed/total nuclei ratio confirmed that 20 lmol/L 
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6-OHDA was highly toxic, resulting in more than 80% CGNs death after 24 h of 
toxin exposure, and that MCM was able to completely revert this effect (Fig. 3.12d).  
 
 
 
 
 
a                                                                          b 
 
     
 
Fig. 3.12 Microglial conditioned medium (MCM) enhances neuronal viability and survival in 
CGNs exposed to 6-OHDA. (a) MTT assay of CGNs cultures treated for 24 h with increasing 
concentrations of 6-OHDA in the presence or absence of 48 h MCM to test its neuroprotection. Each 
point is the mean ± SE of six different experiments run in triplicate; *p < 0.05, ***p < 0.001 with 
respect to the conditions of treatment with 6-OHDA in non-conditioned medium. (b) MTT assay of 
CGNs treated for 24 h with 6-OHDA 20 lmol/L in the presence or absence of medium obtained by 
microglial cells exposed themselves to 6-OHDA 20 lM for 48 h to test its neuroprotection. Each point 
is the mean ± SE of three different experiments run in triplicate; „ p < 0.001 compared to controls; 
***p < 0.001 with respect to the conditions of treatment with 6-OHDA in non-conditioned medium. (c) 
Representative Hoechst staining of apoptotic death. CGN cultures were treated for 24 h with 20 lmol/L 
6-OHDA in the presence or absence of MCM. (d) Quantification based on count of condensed and 
normal nuclei following Hoechst staining. Bars are the mean ± SE of three different experiments run in 
duplicate; „ p < 0.001 respect to the control condition, ***p < 0.001 with respect to the condition of 
treatment with 6-OHDA in non-conditioned medium. Calibration bar 40 lm. 
 
   85 
 
3.2.2 Neuroprotection of microglia conditioned media from apoptotic 
death induced by Aβ42 in cultures of rat cerebellar granule cells 
 
 
We tested the microglia neuroprotective model in AD-like neurodegeneration induced 
by Aβ42 on CGNs. The CGNs were treated with a crude preparation of Aβ42 (40µM) 
added directly in the medium serum free or in the presence of microglia conditioned 
media MCM48h or DC for 24h. Exposure of CGNs cells to 40µM of Aβ42 reduced the 
cellular viability by approximately 50% (Fig. 3.13) as determined by the MTT with 
respect to the control (cells shifted in medium serum free, in MCM48 and DC).  
The presence of the two conditioned media do not reverted the Aβ42-induced damage 
on CGNs. 
 
 
                      
3.13 Effect of microglial-conditioned media against Aβ42–induced toxicity in CGNs. CGNs cells 
were treated with Aβ42 (40µM) added directly in the media serum free or added to the cells shifterd 
with two microglial-conditioned media: MCM48h or DC, for 24h. The cellular viability was evaluated 
by MTT assay and the data were expressed as percentage of control (non treated cells). The control 
treatment is set to 100%. Error bars are means ±S.E.  
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3.2.3 Neuroprotection of microglia conditioned media from apoptotic 
death induced by staurosporine in cultures of rat cerebellar granule 
neurons 
 
We examined the neuroprotective role of microglia conditioned media on CGNs 
challenged with staurosporine-induced apoptosis. 
Exposure to staurosporine resulted in apoptotic death of CGNs, as revealed by the 
appearance of condensed nuclei in Hoechst stained cultures (Fig. 3.14A). Through 
cell counting, it was determined that about 30% of cultured neurons were apoptotic by 
the end of the 24-h treatment and that MCM, and to a greater extent DCM, 
significantly protected CGNs from the neurotoxic insult (Fig. 3.14B). A similar 
degree of neuroprotection of the media conditioned by microglia was assessed by 
using the MTT assay to evaluate cell viability (Fig. 3.14C).  
 
 
 
Fig. 3.14 Hoechst stain of control CGC at 8 DIV (A) or corresponding cultures treated for 24 h with 
staurosporine (B). Arrows point at condensed nuclei; calibration bar, 30_m. (C) Cell count of 
condensed and total nuclei after Hoechst stain. Data were expressed as percentage of condensed nuclei 
over total stained nuclei. Bars aremeans°æS.E. from four to eight cultures for each condition. **P < 
0.001, *P < 0.01 compared to control; #P < 0.05, ##P < 0.01 compared to staurosporine in non-
conditioned medium. Newman–Keuls multiple comparison test after ANOVA. (D) MTT assay on 
corresponding CGC cultures. Bars aremeans°æS.E. from four to eight cultures for each condition. *P < 
0.05, **P < 0.001 compared to control; #P < 0.05, ##P < 0.001 compared to staurosporine in non-
conditioned medium. Newman–Keuls multiple comparison test after ANOVA. 
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3.2.4 Neuroprotection of microglia conditioned media from apoptotic 
death induced by glutamate in cultures of rat cerebellar granule 
neurons 
 
Sub-chronic glutamate excitotoxicity obtained through continuous exposure of the 
cultures to 100µM glutamate added to the serum-free medium, resulted after 24 h in 
the appearance of a sizeable number of condensed nuclei (Fig. 3.15A). Quantification 
through cell counting demonstrated around 20% of apoptotic neurons and also in this 
case MCM and DCM significantly protected from death neurons challenged with the 
excitotoxic insult (Fig. 3.15B). By assessing neurotoxicity through cell viability 
evaluated by MTT assay, we could confirm the significant neuroprotective action of 
media conditioned by microglia (Fig. 3.15C). Acute excitotoxicity, obtained through a 
short pulse of exposure of granule neuron cultures to glutamate in the absence of 
magnesium, resulted after 24h of subsequent incubation in the serum-free medium in 
massive neuronal death, as previously described (Ciani E et al., 1996). Under these 
conditions, neuronal death over the 24h period considered derives from a mix of 
apoptotic and necrotic mechanisms (Ankarcrona et al.,1995; Slagsvold et al., 2000) 
and cannot be reliably quantified through Hoechst stain. For this reason, we evaluated 
cell death from the ratio between PI positive cells (dead cells) and total cells present 
in the culture after 24 h from the initial excitotoxic insult (dead cells plus FDA-
stained viable cells).  
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Fig. 3.15 Hoechst stain of control CGC at 8 DIV (A) or corresponding cultures treated for 24 h with 
glutamate (B). Arrows point at condensed nuclei; calibration bar, 30_m. (C) Cell count of condensed 
and total nuclei after Hoechst stain. Data were expressed as percentage of condensed nuclei over total 
stained nuclei. Bars are means°æS.E. from 8 to 20 cultures for each condition. *P < 0.001 compared to 
control; #P < 0.001 compared to glutamate in non-conditioned medium. Newman–Keuls multiple 
comparison test after ANOVA. (D) MTT assay on corresponding CGC cultures. Bars are means°æS.E. 
from four to eight cultures. *P < 0.001 compared to control; ##P < 0.01, #P < 0.05 compared to 
glutamate in non-conditioned medium. Newman–Keuls multiple comparison test after ANOVA.  
 
As shown in Fig. 3.16A, the delivery of this excitotoxic insult to granule neuron 
cultures resulted in large decrease of FDA stained viable cells and corresponding 
increase of PI-stained dead cell nuclei. Cell counting (Fig. 3.16B) allowed to 
quantitatively estimate cell death at a value of at least 50% and to assess that, while 
MCM and to a greater extent DCM showed a tendency towards neuroprotection, this 
effect did not result statistically significant. In order to try to separate the effects of 
apoptosis from those of necrosis in this model of glutamate toxicity, we made 
experiments based on the measure of caspase 3 activity by determining it through the 
fluorogenic substrate Ac-DEVD-AMC (Calbiochem). While also in this case there 
was a tendency of MCM, and even more of DCM, to reduce caspase 3 activity in 
glutamate-treated cells, the results did not reach statistical significance (data not 
shown). Our present data substantially extend available information on the ability of 
microglia conditioned media to protect from death neurons challenged with 
neurotoxic stimuli (Polazzi et al., 2001; Toku et al., 1998). 
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Fig. 3.16 (A) FDA (upper panels) and PI (lower panels) staining of CGC in control conditions and 24 h 
after an acute excitotoxic insult of glutamate. Calibration bar, 45_m. (B) Cell counting of FDA- and PI-
stained cells in the various experimental conditions. Bars are means°æS.E. from six to eight cultures 
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3.2.5 Identification of putative neuroprotective factor(s) in MCM48h 
 
In an effort to identify the nature of the putative neuroprotective factor(s) present in 
the conditioned medium, we exposed MCM to heath inactivation or to a pre-treatment 
with wide spectrum peptidases/proteases, before testing it for neuroprotection of 
CGNs exposed to 6-OHDA. As shown by Fig. 3.17 (a) and (b), both types of 
treatments resulted in a significant, but not complete abrogation of MCM 
neuroprotection, thus suggesting that peptidic factor(s) certainly contributed to, but 
not completely accounted for this MCM neuroprotective action. 
 
                             
                               
 
Fig. 3.17 MCM protects CGNs exposed to 6-OHDA through partial contribute of peptidic 
factors. CGN cultures were treated for 24 h with 30 lmol/L 6-OHDA in the presence or absence of 
MCM previously heat-inactivated (a) or previously enzimatically treated with proteinase K or 
peptidase (b). CGNs viability has been measured through MTT assay. (a) Bars are the mean ± SE of six 
different experiments run in triplicate; „ p < 0.001 with respect to the conditions of treatment with 6-
OHDA in non-conditioned medium; **p < 0.01 with respect to the conditions of treatment with 6-
OHDA in non-heat-inactivated MCM. (b) Bars are the mean ± SE of six different experiments run in 
triplicate; „ p < 0.001 with respect to the conditions of treatment with 6-OHDA in non conditioned 
medium. **p < 0.01 with respect to the conditions of treatment with 6-OHDA in non-enzymatically-
treated MCM. 
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3.2.6 Identification of molecular weight of the neuroprotective 
factor(s) 
 
To get more information on putative neuroprotective peptide(s), we performed a 
molecular weight based fractionation of MCM, by passing it through filters provided 
with a 10 kDa cut-off, before reconstituting the medium to the initial volume and 
testing it for its neurotoxicity/neuroprotection on 6-OHDA-treated CGNs. By itself, 
none of the two fractions obtained was able to replicate the neuroprotection, as done 
by the complete MCM (Fig. 3.18 a and b). Interestingly, even if the < 10 kDa fraction 
was neurotoxic towards CGNs per se, it significantly protected them from 6-OHDA 
neurotoxicity (Fig. 3.18).    
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Fig. 3.18 Absence of neuroprotection by fractions of MCM obtained through filtration with cut-
off at 10 kDa molecular weight. CGNs cultures were treated for 24 h with 20 lmol/L 6-OHDA in the 
presence or absence of MCM or its fractions containing high molecular weight (> 10 kDa) substances 
and low molecular weight (< 10 kDa) substances. Neuronal death has been measured by Hoechst 
staining (a), followed by nuclei count (b). Bars are the mean ± SE of three different experiments run in 
duplicate „ p < 0.001 with respect to the control medium, #p < 0.001 with respect to control medium 
and MCM; **p < 0.01, ***p < 0.001 with respect to the conditions of treatment with 20 lmol/L 6-
OHDA with non-conditioned medium. Calibration bar 40 lm. 
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3.2.7 Identification of TGF-β2 in the MCM48h 
 
To more precisely target putative neuroprotective peptide(s), we tested MCM for the 
presence of proteins known to be neuroprotective. In particular, we performed 
western blot analysis of both cell lysates and MCM to verify whether some of these 
potentially neuroprotective factors were synthesized by microglial cells and 
accumulated in the medium. We decided to analyze the expression of BDNF, IGF-I 
and TGF-b proteins, as they are known to be potentially synthesized by microglia and 
to be neuroprotective towards CGNs (D’Mello et al., 1993; Lindholm et al., 1993; 
Nakajima et al., 2001; Elvers et al., 2005). As shown in Fig. 3.19, BDNF appeared to 
be synthesized, but not released in the medium by microglia, while IGF-I, TGF-b1 
and TGF-b3 were both present in the cells and released into the medium conditioned 
for 48 h in their precursor high molecular weight forms. TGF-b2 precursor was 
constitutively synthesized by microglia and accumulated into the medium in its active 
form of estimated molecular weight of 12.5 kDa, reaching an apparently high level 
after 48 h of culture.  
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                                                                        Cell lysate       MCM 1mL 
                                                         
                                                                             2 h  48 h                 2 h     48 h                                                  
BDNF 
                                         28 kDa  
 
 
 
IGF-I                                 50 kDa 
 
 
 
 
TGF-β1 
 
 
 
 
 
 
TGF-β2                             50 kDa  
 
 
 
 
 
 
TGF-β3                             50 kDa 
 
 
 
 
 
 
 
Fig. 3.19 Protein expression analysis of potential neuroprotective factors in microglial cells 
cultures and microglial conditioned medium. Microglial BDNF, IGF-I, TGF-b1, TGF-b2 and TGF-
b3 expression and release into the conditioned medium have been detected by using western blot 
analysis on both microglial cell lysates (after 2 h and 48 h of culture) and concentrated aliquots of 
MCM (at 2 h and 48 h). b-Actin staining on microglial cell samples has been performed as a loading 
control. 
 
 
In order to exclude that non-specific TGF-b-like ligands (see below) could interfere 
with the revealed immunoreactivity, we verified through real time PCR whether 
microglial cells actually synthetized TGF-b mRNAs. All the three TGF- b mRNAs 
were synthesized by microglial cells in culture both shortly after plating and after 48 h 
of culture, as shown by the presence of bands of the expected size in the gel and 
byreal time PCR quantification (Fig. 3.20).  
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                            TGF-β1                              TGF-β2                                 TGF-β3 
                            2 h     48 h      b                      2h        48h       b                      2h       48h      b 
         
 
Fig. 3.20 PCR analysis and quantification of TGF-b1, TGF-b2 and TGFb3 expression in 
microglial cells cultures. Microglial TGF-b1, TGF-b2 and TGF-b3 RNA expression have been 
detected by using specific primer pairs through real-time PCR analysis in microglial cell at 2 h and 48 
h. (a) Table of TGF-b1, TGF-b2 and TGF-b3 expression in Dct relative to actin (Dct = Ct of each gene-
Ct of b-actin) at 2 h and the fold-expression of 48 h compared to 2 h. For the 2 h stage, three 
experiments in duplicate were run; for the 48 h, four experiments in duplicate; b is the negative control, 
without cDNA. (b) Representative gel of PCR analysis of microglial TGF-b1, TGF-b2 and TGF-b3 
RNA expression at 2 and 48 h (b is the negative control). 
 
 
Focusing on TGF-b2, which was the only tested peptide present in MCM in its mature 
form, by densitometric quantification of its content in western blots from MCM 
compared with western blots made from known amounts of recombinant TGF-b2, we 
estimated a peptide concentration of about 60 ng/mL in media conditioned for 48 h 
(data not shown). Therefore, TGF-b2 appeared to be a promising candidate as a 
possible neuroprotective agent, being released in MCM at high concentration in its 
active form and having previously shown a neuroprotective action towards CGNs and 
in PD-models (Elvers et al., 2005; Andrews et al., 2006). Attempts to abrogate MCM 
neuroprotection by blocking TGF-b2 with neutralizing antibodies (T4442 from 
Sigma- Aldrich or sc-90 Santa Cruz Biotechnology Inc.) were hampered by the fact 
that concentrations of antibodies still unable to remove the high amount of the peptide 
present in the medium, as verified through immunoprecipitation experiments, resulted 
toxic by themselves to CGNs (data not shown). We, therefore, tried to demonstrate 
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the involvement of TGF-b2 in MCM neuroprotection by using two different 
approaches. First, we tested whether addition of exogenous TGF-b2 to the MCM 
fraction, previously depleted of it through the fractionation procedure, was able to 
restore a neuroprotective action similar to the complete medium. This was actually the 
case, as supplementation of the < 10 kDa MCM fraction with 10 ng/mL, a 
concentration known to exert in vitro biological activity (Elvers et al., 2005) fully 
protected CGNs from exposure to 6-OHDA (Fig. 3.20a). Noticeably, the same 
addition of TGF-b2 to a control medium, not previously conditioned by exposure to 
microglia, was ineffective. This clearly demonstrated that the efficacy of TGF-b2 
neuroprotection depended in our model on the cooperative action with other 
substance(s) present in the conditioned medium, in particular in its low molecular 
weight fraction. Furthermore, addition of exogenous TGF-b2 was also able to 
abrogate the intrinsic toxicity of < 10 kDa MCM fraction, thus recreating the effect of 
the complete conditioned medium (Fig. 3.20a). Second, we tested the role of TGF-b2 
in the neuroprotection granted by MCM by adding to this medium inhibitors of the 
intracellular pathways mediating the receptorial effects of TGF-bs, i.e. the compounds 
SB 431542 and SB 525334 that act on ALK (Activin Receptor-like Kinase)-family 
kinases (Inman et al., 2002; Laping et al., 2002; Grygielko et al., 2005). The 
neuroprotective effect of MCM was significantly attenuated by the ALK antagonist 
SB 431542 (Fig. 3.20 b), thus supporting the role of TGF-b-activated pathway in 
MCM protection of CGNs. A similar effect was also exerted by another ALK 
antagonist, SB 525334 (data not shown). As both these inhibitors are not selective for 
ALK5, which is the specific downstream mediator of TGF- b2, we performed 
experiments able to exclude that other proteins of the activin family acting through 
ALK signaling (Schmierer and Hill, 2007) were involved in MCM-mediated 
neuroprotection.  
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Fig. 3.20 Involvement of TGF-b2 in the neuroprotective action of MCM. (a) Human recombinant 
TGF-b2 (10 ng/mL) was added to the fraction of MCM containing low molecular weight (< 10 kDa) 
substances and its neuroprotective action was compared with that of complete medium on CGN 
cultures treated for 24 h with 20 lmol/L 6-OHDA. Nuclei count after Hoechst staining. Bars are the 
mean ± SE of three different experiments run in duplicate; **p < 0.01, ***p < 0.001 with respect to the 
conditions of treatment with 20 lmol/L 6-OHDA in non-conditioned medium; #p < 0.001 with respect 
to the condition of treatment with fraction of MCM containing low molecular weight (< 10 kDa) 
substances without the addiction of TGF-b2. (b) A specific inhibitor of TGF-bs signal transduction 
pathway, SB 431542 (10 lmol/L), was added to the cultures of CGNs treated for 24 h with 20 lmol/L 6-
OHDA in the presence or absence of MCM. Nuclei count after Hoechst staining. Bars are the mean ± 
SE of two different experiments run in duplicate; *p < 0.05, ***p < 0.001 with respect to the 
conditions of treatment with 6-OHDA in non-conditioned medium; #p < 0.01 with respect to the 
condition in the absence SB 431542. 
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Western blots of four members of activin family showed that only precursor forms of 
these proteins, with estimated molecular weight > 30 kDa, were present in the 
medium conditioned by microglia (Fig. 3.21a). As mature forms of these proteins 
were not detected in MCM, their involvement in neuroprotection was unlike. To 
experimentally support this, we tested whether the neuroprotective effect of MCM 
was preserved after excluding all molecules with molecular weight > 30 kDa through 
selective filtration. Results showed that the conditioned medium deprived of > 30 kDa 
molecules retained its full neuroprotective activity (Fig. 3.21b). As a final experiment, 
we tested whether the putative neuroprotective factor(s) present in the < 10 kDa 
MCM fraction and required to obtain the full TGF-b2-mediated protection were also 
heat-labile molecules. As shown by Fig.3.21, this was not the case, as the 
neuroprotective effect of TGF-b2 was exactly the same when added to the native or to 
the heat-inactivated < 10 kDa fraction, suggesting a nonpeptidic nature of these low 
molecular weight factor(s).     
                              
Fig. 3.21 Low molecular weight, heat-stable factors cooperate with TGFb2 in fulfill its 
neuroprotection. Human recombinant TGF-b2 (10 ng/ mL) was added to the fraction of MCM 
containing low molecular weight (< 10 kDa) substances, previously heat inactivated, then its 
neuroprotective action was compared with that of not heat-exposed medium on CGNs cultures treated 
for 24 h with 20 lmol/L 6-OHDA. Bars represent the mean ± SE of two different experiment run in 
duplicate „ p < 0.001 with respect to the conditions of treatment with 6-OHDA in non-conditioned 
medium; ***p < 0.001 with respect to the corresponding conditions in the absence of TGF-b2 
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CHAPTER 4 
DISCUSSION 
 
Converging evidence from various sources, including pathology, genetics, 
biochemistry, cell biology and animal models suggest that the aggregation of α-syn in 
PD and Aβ in AD play a critical role in the pathogenesis of these complex disorders. 
Hence, strategies aimed at inhibiting and/or reducing the aggregation and amyloid 
fibril formation of these proteins represent a viable therapeutic strategy to combat 
and/or prevent the progression of neurodegeneration in both diseases. Towards 
identifying potent drug-like aggregation inhibitors, E and T, two ICOMT currently 
approved as adjuncts in the therapy of PD, and five other catechol-containing small 
molecules (GA, CA, Q, P and DA) were selected and their effect on the 
oligomerization and fibrillization of α-syn and Aβ42 was investigated using ThT 
fluorescence, TEM and SDS-PAGE analysis. Our results demonstrate that all 
catechols containing compounds shown in Fig. 1 inhibited α-syn and Aβ fibrillization 
in vitro and showed protective effects against α-syn and Aβ42-induced toxicity in 
PC12 cells. At 1:1 protein to compound ratio, all compounds tested showed > 90% 
inhibition of α-syn fibrillization and blocked the growth and seeding capacity of α-syn 
fibrils. However, at lower protein to compound ratios (10:5 and 10:1) only Q, T, E 
showed the strongest inhibition. CA and P were the least effective at lower molar 
ratios and showed only 40-50% inhibition of α syn fibril formation. To probe the 
specificity of these compounds towards α-syn, we determined their capacity to inhibit 
the fibrillization of Aβ42 monomers, PFs and fibrils. All the compounds exhibited 
reduced (55-75%) inhibitory activity against the fibrillization of LMW and PF Aβ42, 
with the exception of Q, which resulted in >90% reduction in the fibrillization of 
Aβ42 fibril formation. When we examined the effect of these compounds on the 
fibrillization of Aβ42 PFs, we observed that T, E, and DA, showed greater inhibition 
(80-90%), with Q being the most effective compound. By TEM analysis, we did not 
observe significant differences in the structural properties of the aggregates and fibrils 
formed among the various compounds tested. There are several mechanisms by which 
these compounds could inhibit amyloid formation, including their ability to: 1) 
stabilize the native monomeric state of amyloid; 2) target different intermediates on 
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the amyloid pathway and block their conversion to fibrils; 3) alter the aggregation 
pathway in favour of non-amyloidogenic aggregates. In the case of α-syn, both SDS-
PAGE analysis and TEM analysis demonstrate that the presence of these compounds 
enhances the solubility of α-syn (Fig. 3.2). On the other hand, none of the compounds 
tested were shown to stabilize monomeric Aβ42, instead the efficacy of these 
compounds appears to be linked to their ability to interfere with Aβ42 aggregation at 
different intermediate stages on the amyloid pathway (Fig. 3.6A and Fig. 3.7A). All 
compounds tested were shown to promote the formation of large non-fibrillar 
aggregates and/or protofibrillar species as discerned by TEM (Fig. 3.6B and Fig. 
3.7B) and the reduced solubility of Aβ42 in presence of some compounds, despite the 
fact incubation with such compounds results in significant reduction in the ThT 
signals. Consistent were the TEM data, we failed to detect significant accumulation of 
monomeric Aβ42 after 96 hr of incubation in the presence and absence of compounds. 
Interestingly, each of the compounds appears to exert very specific effects and show 
preference for targeting different aggregation state on the amyloid pathway. For 
example, while T and E were equally effective in blocking the fibrillization of Aβ42 
LMW and PF and showed strong inhibition of Aβ42 fibril growth and seeding 
capacity, DA and Q were most effective against the fibrillization of Aβ42 LMW and 
PF, but did not show significant inhibition of Aβ42 fibril growth and seeding 
capacity. Furthermore, incubation of each compound with Aβ42 resulted in the 
accumulation of Aβ42 aggregates of distinct size and morphological properties (Fig. 
3.6B and Fig. 3.7B). Together, these results suggest that the presence of the catechol 
moiety in these compounds is sufficient to impart on them an anti-amyloidogenic 
activity against α-syn and Aβ42. However, the TEM and solubility studies 
demonstrate that the compounds interfere with the fibrillization of Aβ42 and α-syn via 
distinct mechanisms. This hypothesis is further supported by our findings that all the 
compounds showed strong inhibition of α-syn fibril growth and seeding capacity, 
whereas only T and E were effective in blocking the growth and seeding capacity of 
Aβ42 fibrils. The remaining (P, CA, GA, Q, and DA) compounds showed minimal 
effect even at 1:1 molar ratio, in contrast to their ability to block the seeding capacity 
of α-syn under similar conditions. To determine if the specificity and potency of these 
compounds is mediated by their interaction with specific sequences and/or structural 
motifs within these two proteins, we sought to determine which residues interact with 
the most potent compounds, Q, T and E using NMR. These studies did not show any 
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significant chemical shift changes for any of the compounds, with the exception of 
very minor chemical shift changes for His50 and some N terminal residues, 
suggesting that there is no direct binding of the compounds to the backbone of α-syn 
in its monomeric state. However, an increase in NMR signal intensity was observed in 
the presence of E and T for a large number of residues in the N-terminal domain of α-
syn, in particular in the NAC region. This is in clear contrast, to the action of the 
polyphenols (-)-epigallocatechin gallate (EGCG), which binds to the backbone of 
monomeric α-syn and Aβ40, decreases the NMR signal intensity of monomeric α-syn 
and redirects both α-syn and Aβ40 into unstructured off-pathway oligomers 
(Ehrnhoefer et al, 2008). EGCG targets the polypeptide main chain that is identical in 
all proteins and easily accessible under unfolded conditions (Ehrnhoefer et al, 2008). 
In contrast, ThT fluorescence, SDS-PAGE and TEM measurements indicate that the 
COMT inhibitors appear to target a conformational feature of oligomers. Currently it 
is not known what this conformational feature is, but hydrophobic patches formed in 
oligomers in a rather unspecific manner could be a potential target. Thus, the COMT 
inhibitors or their scaffold are potentially more useful lead compounds than EGCG, as 
they preferentially bind to protein aggregates and not to unfolded polypeptide 
backbones. 
 
 
Entacapone (E), tolcapone (T) and related catechols protect against extracellular 
a-syn and Aβ42-induced toxicity in PC12 cells  
 
To determine if the ability of these compounds to block and/or alter the fibrillization 
pathway of Aβ42 and α-syn fibrillization could translate into protection against Aβ42 
and α-syn cellular toxicity, we evaluated their protective effect in the cell culture 
using different assays. At concentrations that showed significant inhibition of Aβ42 
and α-syn fibrillization, all the compounds were shown to protect PC12 cells from 
Aβ42 and α-syn-induced cytoxicity, by mechanisms that are directly linked to their 
ability to modulate the fibrillization of both proteins. These results are in agreement 
with previous studies. Several small polyphenols molecules were shown to exhibit 
strong antiamyloidogenic and neuroprotective properties in vitro and in vivo. 
Bastianetto et al. reported on the neuroprotective effects of GA and other green and 
black tea catechin gallate against Aβ40 in neuronal cell cultures (Bastianetto et al, 
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2006). Other groups have also demonstrated that cathechol and polyphenol 
compounds as potent antiamyloid agents and investigated the chemical and structural 
properties underlying their potency. However, to the best of our knowledge the anti-
amyloidogenic properties of the two nitrocatechols E and T, already known for other 
biological activities, i.e. antioxidants and ICOMT, have never been described in 
literature. Although there is strong evidence in support of the protofibril hypothesis, 
the exact mechanisms by which protofibrils cause toxicity and the identity of the toxic 
species remain unknown. Protofibrils represent a heterogeneous mixture of aggregates 
of various size and morphologies, some of which are likely to contribute to toxicity. It 
is noteworthy, that all the fibrillization inhibitors reported in the literature, including 
those that protect against Aβ and α-syn toxicity exert their effect by acting at an 
intermediate step along the amyloid pathway, i.e. there are no known small molecule 
inhibitors that stabilize monomeric Aβ and α-syn. As shown in Figures 3.6 and 3.7, 
the different compounds we tested appear to stabilize or induce the formation of 
prefibrillar aggregates of distinct morphologies. Together, these results suggest that 
these molecules act by altering the structure of the aggregates and diverting toxic 
intermediates towards off-pathway non-toxic species. Studies from several groups 
have shown that small molecules, including inositol stereoisomers (McLaurin et al, 
2000), (-)-epigallocatechin gallate (EGCC) (Ehrnhoefer et al, 2008) as well as Aβ42 
derived peptides (Fradinger et al, 2008) were shown to alter the toxic properties of Aβ 
by stabilizing and/or inducing structural remodeling of protofibrillar and fibrillar 
aggregates. Resveratrol blocks Aβ toxicity without inhibiting oligomer formation 
(Feng et al, 2000). Moreover, recent studies from our group (Jan et al, 2008) and 
others (Wagulis et al, 2005) suggest that amyloid toxicity requires an on-going 
fibrillization process, i.e. the presence of protofibrils or fibril is not sufficient to cause 
toxicity unless these species are undergoing an on-going fibrillization process. 
Previous studies with DA and other catecholamines, e.g. apomorphine (Lashuel et al, 
2000), linked their anti-amyloidogenic properties to their ability to undergo rapid 
autoxidation in aqueous solution, suggesting that one or more oxidation products is 
responsible for their inhibitor properties (Norris et al, 2001). However, the two major 
products of the catecholamine oxidation, i.e. quinines and aminochromes, are 
relatively unstable and difficult to isolate. In order to verify this hypothesis, the 3-
methoxytyramine, the major metabolite of dopamine, was tested in the same working 
condition and in the presence of the two proteins, i.e. α-syn and Aβ42. As expected, 
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the results obtained confirmed that the methylated derivative of dopamine had no 
effect on the protein fibrillization process (data not shown). The mechanism by which 
catechol containing compounds block protein fibrillization remains controversial. 
Conway et al. reported that DA stabilise α-syn PFs by forming a DA-α-syn adduct 
(20). More recently, Norris et al. suggested a novel mechanism of action in which the 
dopaminochrome, the oxidized product of DA, inhibits α-syn fibrillization by 
interacting with the specific amino acid motif in the C terminus and NAC region of α-
syn (Norris et al, 2005;Li et al, 2004; Jarret et al, 1993; Herrera et al, 2008; Yamin et 
al, 2005). Given the structural similarity amongst E, T and other known 
antiamyloidgenic catechol derivatives such as DA and Q, it is plausible to speculate 
that a shared mechanism may underlie the effectiveness of all these compounds. All 
seven molecules shown in Table 3.1 have in common the fact that each possesses at 
least one aromatic ring with catechol moiety. 
 
Relevance to α-syn toxicity and Parkinson’s disease 
 
Although predominantly a cytosolic protein, several lines of evidence suggest a 
potential role of extracellular α-syn in mediating α-syn toxicity, Lewy body formation 
and the pathogenesis of PD and related synucleinopathies. These lines of evidence 
include: 1) recent studies from different laboratories which have shown that some 
monomeric and/or soluble aggregated forms of α-syn are secreted and can be detected 
in the blood plasma and cerebrospinal fluids of patients suffering from PD and related 
synucleinopathies (Borghi et al, 2000; Tokuda et al, 2006); 2) the fact that exogenous 
aggregated forms of α-syn have been shown to induce microglial activation, stimulate 
the production of reactive oxygen species (Zhang et al, 2005)), and pro-inflammatory 
factors (Klegeris et al, 2008) and are toxic to mammalian cells and primary neurons 
(El-Agnaf et al, 1998; Sung et al, 2008); 3) studies which have shown that the cellular 
uptake of extracellular α-syn occurs by passive diffusion (monomers) or via receptor 
mediated endocytic pathways (Ahn et al, 2006) (oligomers and protofibrils), 
depending on the aggregation state of α-syn (Lee et al, 2008) 4) the fact that small 
amounts of extracellular α-syn aggregates can efficiently catalyze the aggregation of 
intracellular α-syn inclusions. Specifically, Luk et al demonstrated that α-syn fibrils, 
prepared from recombinant full length or truncated α-syn, were uptaken by cells 
within cultures and act as seeds that catalyzed the aggregation and conversion of 
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soluble intracellular α-syn into LB-like inclusions (Luk et al, 2009). Finally, 5) 
Desplats and colleagues demonstrated neuron-to-neuron and neuron-to-glia 
transmission of monomeric and aggregated α-syn species in vivo and in cell cultures 
(Desplats et al 2009). These studies suggest that the release and uptake of monomeric 
and soluble aggregates of α-syn plays a central role in inclusion formation, neuronal 
cell death and spreading of α-syn pathology in PD. Therefore, targeting the 
aggregation of extracellular α-syn and/or promoting their clearance have emerged as 
viable therapeutic strategies for PD and related synucleinopathies. In this regard, the 
identification of small molecules that block or reverse the aggregation of extracellular 
α-syn is desirable. Herein, we demonstrated that entacapone, tolcapone and related 
catechols inhibit α-syn fibrillization in vitro and prevent the formation of toxic 
aggregates as discerned by their protection against α-syn induced extracellular 
toxicity in PC12 cells. Currently, the most effective treatment for PD continues to be 
the administration of L-DOPA together with a peripheral AADC inhibitor that is 
unable to enter the central nervous system. However, the amount of L-DOPA 
reaching the brain after oral administration is very low (about 5-10%). Furthermore, 
the subsequent metabolism of L-DOPA by catechol-O-methyltransferase (COMT) 
clearlylimits its availability in the brain. The two COMT inhibitors E and T, approved 
as adjuncts in the therapy of PD, increase the availability of L-DOPA for conversion 
to dopamine in the brain (Bonifacio et al, 2007) mainly by preventing the extensive 
metabolism of L-DOPA through O-methylation in the periphery (E and T) and partly 
in brain (T) (Lapish et al, 2009) However, the potential for the use of T as 
neuroprotective drug in AD or PD is limited due to the fact that it has been shown to 
cause severe hepatotoxicity resulting in its withdrawal from the market in many 
countries leaving entacapone as the only COMT inhibitor presently available in the 
clinic for the treatment of PD (Assal et al, 1998). However, recent studies 
demonstrate that tolcapone can be used with benefit when the liver function is 
actively monitored (Antonini et al, 2008; Truong et al, 2009). Although these two 
compounds share the same pharmacophore, their pharmacokinetic profiles are 
remarkably different (Navardi et al, 2006). Indeed, studies with rats have shown that 
tolcapone has a longer duration of action than entacapone and is both a central and 
peripheral COMT inhibitor, whereas entacapone is essentially a peripheral inhibitor 
(Di Stefano et al, 2009). However, the benefits of both entacapone and tolcapone in 
the L-DOPA treatment of patients suffering of Parkinson's disease were proved 
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(Haefeli et al, 2007; Damier et al, 2008). 
 
In summary, our study showed that entacapone and tolcapone are potent inhibitors of 
α-syn and Aβ oligomerization and fibrillogensis and that the inhibition of the 
aggregation results in a protection against extracellular toxicity induced by the both 
proteins. Our results provide additional evidence for the potential of catechols as 
antiamyloidogenic agents and and demonstrate that entacapone and tolcapone belong 
to the classes of multifunctional drugs (Navardi et al, 2005) since they can inhibit 
COMT, act as good antioxidants and as effective inhibitors of protein aggregation 
(Bertolini et al, 2007). Whether the anti-amyloidogenic property of entacapone and 
tolcapone and the protection against α-syn extracellular toxicity contribute to their 
clinical benefits and enhanced symptomatic treatment of PD or not remains to be 
determined. Nonetheless, our findings suggest that the structure entacapone and 
tolcapone constitute molecular scaffolds that could guide the development of more 
potent inhibitors of amyloid formation and toxicity. Chemical modifications of 
entacapone and tolcapone can be envisaged in order to optimize its pharmacokinetic 
profile especially by avoiding hepatotoxicity (Boelsterli et al, 2006), modeling its 
peripherical metabolism and increasing its BBB permeation. 
 
Protection of microglia conditioned media in PD-like neurodegeneration models 
induced by 6-OHDA toxin 
 
Finally, we analyzed the neuroprotective effect of microglia conditioned media 
towards different insults. Our present data substantially extend available information 
on the ability of microglia conditioned media to protect from death neurons 
challenged with neurotoxic stimuli (Polazzi et al, 2001, Toku et al, 1998). It was 
previously demonstrated such a neuroprotective effect on a model of apoptotic 
neuronal death caused by the shift of mature CGC cultures from depolarizing to non 
depolarizing conditions (Polazzi et al, 2001) and we now show a strong and highly-
specific neuroprotective action of microglia conditioned medium on an in vitro model 
of Parkinson-like neurodegeneration, the 6-OHDA-induced CGNs death. With the 
present report, we demonstrate a novel neuroprotective action of MCM on 6-OHDA 
neurotoxicity in CGNs, having previously described similar effects in different 
models of CGNs induced apoptosis (Polazzi et al. 2001; Eleuteri et al. 2008). 6-
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OHDA is a neurotoxin with selectivity for dopaminergic neurons because of the 
presence of the dopamine transporter expressed in these cells, but CGNs are quite 
sensitive to 6-OHDA too (Dodel et al. 1999; Lin et al. 2003; Chen et al. 2004; Ma et 
al. 2006; Monti et al. 2007). CGNs have been used here as they are commonly 
considered a good model to study the cellular, biochemical and molecular 
mechanisms of neuronal survival/death and are among the most widely-used neuronal 
primary cultures (Contestabile 2002). In this model, 6-OHDA results in 
neurodegeneration presenting most of the characteristic features of Parkinson-like 
neuronal death, i.e. an apoptotic process with oxidative stress, proteasome impairment 
and protein aggregation (Dodel et al. 1999; Lin et al. 2003; Chen et al. 2004; Ma et al. 
2006; Monti et al. 2007). Here, we have found that the pro-survival action exerted by 
MCM completely reversed 6-OHDA neurotoxic effect, not with standing its high 
toxicity, thus suggesting a high specificity of MCM secreted survival factors for this 
model of cell death. Indeed, in different models of CGNs death, MCM only partially 
counteracted neurotoxic insults (Polazzi et al. 2001; Eleuteri et al. 2008).  
We extended the neuroprotective analysis of the conditioned media (MCM48 and 
DC) against the Aβ42-induced toxicity in CGNs. Using this in vitro models of AD-like 
neurodegeneration we did not find protection against the Aβ42-induced toxicity 
already seen for the inhibitors of the α-syn and β-amyloid aggregation. We also tested 
the neuroprotective effect of microglia conditioned media against excitotoxicity and 
staurosporine-induced apoptosis.  
Staurosporine, a broad spectrum protein kinase inhibitor, is a wellknown inducer of 
apoptosis in various types of cells, including CGCs (Franco-Cea et al, 2004; 
Melchiorri et al, 2002). As indicated above, glutamate may induce neuronal death 
through both apoptotic and necrotic mechanisms (Ankarcrona et al, 1995; Slagsvold 
et al, 2000), apoptosis being the prevalent modality of cell death when the excitotoxic 
stimulus is mild and long-lasting (sub-chronic treatment) as previously described 
(Leng et al, 2006), and necrosis prevailing for short pulses of glutamate given in the 
absence of magnesium to maximize the involvement of NMDA receptors in the 
excitotoxic insult (acute treatment). In the present experiments, having delivered the 
excitotoxic stimulus in both ways, we were able to demonstrate a significant 
neuroprotection of media conditioned by microglia in the case of the sub-chronic mild 
treatment but not in the case of the acute excitotoxic treatment. The similarity of the 
glutamate mild excitotoxic stimulus with the neuroprotective effect noticed for 
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staurosporine treatment, a recognized apoptosis inducer suggests that microglia 
conditioned media preferentially protect neurons challenged with apoptotic death 
stimuli. While one should be obviously cautious in extending findings obtained in 
culture to the balance apoptosis/necrosis in vivo, this may reflect an in vivo 
differential involvement of microglia in chronic vs. acute insults. Our present data 
also demonstrate that the neuroprotection granted by a medium conditioned for 48 h 
by microglia is replicated, and indeed some what enhanced, by a medium conditioned 
by microglia for only 24 h but previously exposed for 24 h to apoptotic neurons. As 
previously discussed (Polazzi et al, 2001), this result strongly suggests that apoptotic 
neurons release in the medium diffusible factors that are in turn able to elicit an 
increased production of neuroprotective substances from microglial cells. This 
suggestion has recently received an important confirm from  a study demonstrating 
that media exposed to neurons challenged with insults of moderate level, 
preferentially elicit the production of neurotrophins from microglia (Lai et al, 2008). 
The use of this experimental approach, or of other similar approaches, is of interest as 
it is potentially able to overcome some of the limitations that are inherent to the use of 
separate microglia and neuronal cultures to study the relationships between the two 
players. Indeed, they allow to re-create a form of reciprocal cross-talk of functional 
significance, in conditions of physical separation of the two cell populations. This 
situation may be advantageous, with respect to co-culture conditions (Neumann et al, 
2006; Polazzi et al, 2001) in order to identify specific factors released in the media 
and responsible for the reciprocal functional influence and the neuroprotective action 
of microglia. Indeed, while the use of co-cultures has the advantage of creating 
conditions more similar to the in vivo situation, it renders more complicated to 
attribute the production of specific molecules to neurons or to microglia, as they are 
obviously mixed in the medium.  
This neuroprotection is exerted through the release into the medium of peptidic 
molecules, which cooperate with low molecular weight, heat-resistant factor(s). 
Moreover, based on multiple evidence, we have identified TGF-b2 as one of these 
neuroprotective agents. As outlined in the introductory section, microglia can secrete 
inflammatory cytokines and other neurotoxic molecules, but also neuroprotective 
factors. A robust inflammatory reaction is observed in PD and other 
neurodegenerative pathologies and reactive microglia are prominent in affected brain 
areas of these patients (recently reviewed by Klegeris et al. 2007; McGeer and 
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McGeer 2008; Smith 2008; Villoslada et al. 2008; Whitton 2007). Therefore, 
blocking inflammation or shifting the balance from pro-inflammatory to anti-
inflammatory states of microglia offers a promising strategy for therapy. In this 
setting, the knowledge of the neuroprotective mechanisms of microglia, coming out 
from in vitro studies of neuron/microglia cross-talk, may help to identify and target 
specific microglial molecules accounting for neuronal survival. Moreover, we have 
demonstrated here that MCM exerts its neuroprotective effect even if microglia are 
exposed themselves to 6-OHDA, thus suggesting that this neurotoxin does not induce 
microglial pro-inflammatory activation. We further provide evidence that TGF-b2 
accumulated in the medium conditioned by microglial cells is an essential, even if not 
unique, factor mediating the MCM neuroprotective effect. Indeed, addition of the 
exogenous peptide to the conditioned medium fraction, previously depleted of 
endogenous TGF-b2 through molecular weight-based fractionation, was able to 
restore the neuroprotective action of the complete medium and also to efficiently 
counteract the intrinsic toxicity of this < 10 kDa MCM fraction towards CGNs. On 
the other hand, TGF b2 requires the presence of at least one factor released by 
microglia in this low molecular weight range to ensure its neuroprotective action. This 
is demonstrated by the fact that the > 10 kDa MCM fraction, in which TGF-b2 is 
present in large amount, lacks neuroprotection by itself and that the addition of the 
exogenous peptide to an unconditioned medium is ineffective too. The finding that 
TGF-b2 needs to cooperate with other factors to explicate its biological activity on 
CGNs is in agreement with previous data (Kane et al., 1996), demonstrating that this 
cytokine differentially regulates cerebellar granule cell neurogenesis depending on the 
presence of serum factors. Regarding the possible cooperation of other factors with 
TGF-b2, it should be considered that the conditioned medium here used derives from 
unstimulated cultured microglia. While evidence exists for functional interactions 
modulating TGF-b activity in response to pro-inflammatory cytokines, such as 
interleukin 6 (Samanta et al., 2008), no production of these cytokines does occur from 
primary microglia not stimulated with LPS (lipopolysaccharide) or other activating 
factors (Horvath et al., 2008; Vollmar et al., 2008).We also provide pharmacological 
evidence for the neuroprotective role of TGF-b2 contained in MCM, by significantly 
decreasing its efficacy through an antagonist of its main receptor/transduction system, 
which acts through kinases of ALK family (Laping et al. 2002; Grygielko et al. 2005). 
Since this pharmacological tool could not unequivocally identify TGF-b2 as the 
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neuroprotective factor, because of the possible interference with other proteins acting 
through ALK pathway, we verified that our cultured microglial cells produced the 
specific mRNA for TGF-b2, as well as for TGF-b1 and TGF-b3. Notwithstanding 
some authors could not detect TGF-b2 production in microglia in early studies 
(Morgan et al. 1993; Constam et al. 1992), more recently other groups demonstrated 
the microglial expression of TGFb2 RNA and protein both in vitro and in vivo (De 
Groot et al. 1999; Ma and Streilein 1999; Yuan and Neufeld 2001). Our PCR analysis 
revealed a continuous production of TGF-b2 mRNA from microglial cells throughout 
the culture period that could well account for the accumulation of the mature form of 
the protein in the medium after 48 h. Furthermore, we demonstrated that other 
proteins of the TGF-bs family, which could be involved in microglial neuroprotective 
action, including activins, nodal and vg-1 (Schmierer and Hill, 2007), were released 
in the conditioned medium at molecular weight > 30 kDa and thus could not 
contribute to neuroprotection as MCM deprived of its > 30 kDa fraction retained its 
full neuroprotective capacity. These experiments, together with our demonstration 
that addition of exogenous TGF-b2 to the fraction of MCM previously deprived of it 
through selective filtration efficiently granted neuroprotection, strongly support our 
identification of TGF-b2 as a neuroprotective factor constitutively released by 
microglia in its medium. Microglia-conditioned medium inactivation shows that 
neuroprotection granted against 6-OHDA toxicity is in part related to heat-resistant 
molecule(s), as the effect does not completely disappear after heat inactivation or 
peptide enzymatic destruction of the medium. This is in agreement with previous 
results, showing that the neuroprotective action of MCM on neurons in different 
neurodegenerative conditions was not completely abolished by heat inactivation 
(Toku et al., 1998; Zietlow et al., 1999; Park et al., 2001; Polazzi et al., 2001). Present 
experiments of heat inactivation on the < 10 kDa MCM fraction demonstrate the 
presence in this fraction of heat-resistant neuroprotective molecule(s), which are 
required to ensure the full protection of the complete medium or of the exogenous 
TGF-b2 added to this same fraction. Hypotheses on the possible nature of heat 
resistant neuroprotective molecule(s) are at present speculative, as they obviously 
require to be subjected to specific experimental analysis. On the basis of literature 
data, potential candidates may belong to prostaglandins and other lipids or sugars, as 
low molecular weight molecules of this kind are known to be released by microglia 
and to result neuroprotective under some conditions (Hicks et al. 1998; Bachis et al. 
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2002; Carrasco et al. 2008; Zhang et al. 2008). The family of TGF-bs comprises 
multifunctional growth factors abundantly expressed in the nervous system and 
promoting neuronal survival in a variety of physiological and neuropathological 
conditions (Flanders et al. 1998; Krieglstein et al. 2002). TGF-b2, in particular, 
protects neurons from excitotoxic insults, promotes differentiation and survival of 
nigral dopaminergic neurons, modulates CREB (cAMP-response element binding 
protein) activity in hippocampal neurons, thus promoting synaptic plasticity, and 
negatively regulates the inflammatory response of the central nervous system (Bruno 
et al. 1998; Andrews et al. 2006; Roussa et al. 2006; Fukushima et al. 2007; Siglienti 
et al. 2007). Cerebellar granule neurons have been demonstrated to be a target of 
TGF-b2 during development. In particular, TGF-b2 has been shown to take part in the 
neurogenesis of this neuronal population through regulation of precursor proliferation, 
apoptotic elimination and maturation (Constam et al. 1994; Kane et al. 1996; de Luca 
et al. 1996; Kaltschmidt and Kaltschmidt 2001; Elvers et al. 2005). Our results 
indicate that TGF-b2, by acting together with other microglia-derived molecules, 
represents a survival factor for these neurons when they are exposed to a neurotoxic 
insult, such as the one represented by 6-OHDA. The interest of this observation is 
increased by the fact that 6-OHDA is a known neurotoxin for dopaminergic nigral 
neurons found to massively degenerate in Parkinson’s disease and by the fact that 
TGF-b2 protects these neurons both in vitro and in vivo (Macauley et al. 2004; 
Roussa et al. 2006). Furthermore, transgenic mice expressing low levels of TGF-b2 
showed an age-related nigro-striatal dopaminergic deficit (Andrews et al. 2006) and a 
recent population study preliminarily demonstrated a trend towards association of the 
5¢ region of TGF-b2 gene and susceptibility to PD (Goris et al. 2007; Klegeris et al. 
2007). Thus, our present study should stimulate novel researches on the role played 
by microglia in the beginning and progression of PD, with the aim of identifying new 
potential targets for therapy. Another member of the same protein family, TGFb1, has 
been reported to be potentially neuroprotective under various experimental conditions 
(Flanders et al. 1998; Zhu et al. 2002, 2004; Boche et al. 2003). Our microglial cells 
expressed both mRNA and precursor of the protein, but no accumulation of mature 
TGF-b1 was detected in MCM even after 48 h of culture, thus suggesting that this 
factor does not play a role in MCM neuroprotection. The relevance of our present 
findings should be discussed with respect to how and to what extent the artificial 
situation of in vitro isolation of microglial cells reflects the situation occurring in 
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vivo. In vivo ‘resting microglia’ is actually continuously active (Raivich 2005) and 
‘activated microglia’ is present in the brain not only with harmful phenotypes, but 
also with beneficial phenotypes that actively contribute to 
 imit neuronal damage and to promote neuron recovery (Schwartz et al. 2006). 
However, this ‘neuroprotective phenotype’ is still not fully characterized. 
Accordingly, in vivo immunosuppressant treatment inhibits the neurodegenerative 
role of microglia in a PD rat model, without completely blocking microglial activation 
itself (Wright et al. 2008). The various microglial states are not autonomously 
determined by microglial cells but are, instead, the result of a continuous and 
reciprocal exchange of molecular messages (Kreutzberg 1996; Neumann 2001; 
Polazzi and Contestabile 2002, 2006; Schwartz et al. 2006). The impossibility to re-
create such complex interrelationships in in vitro systems is an obvious limitation of 
studies based on interactions in co-cultures or on the use of conditioned media to 
reciprocally test the responses of the different players. On the other hand, as 
considered in the introduction, this approach makes easier to isolate and identify 
specific factors involved in microglia-neuron cross-talk, as it is the case for TGF-b2 
in the present study. In the case of experiments here presented, for instance, results 
suggest a continuous production of neuron survival factors from microglia and, 
therefore, they are consistent with the idea that microglia constitutively serve a 
functionally supportive and neuroprotective role (Streit et al. 2008). While obtained in 
separate cultures, our result, demonstrating that 6-OHDA toxicity towards microglia 
does not disrupt the neuroprotective action of the conditioned medium, suggests that 
the occurrence of neurotoxic insults affecting both neurons and microglia in vivo may 
not compromise microglial neuroprotection. Furthermore, in line with the idea that 
microglia in culture may reflect a functional state of activation of these cells, in some 
way similar to a state found in chronic neurodegenerative diseases (Streit et al. 1999), 
these experimental evidences in culture represent an important conceptual 
advancement in understanding microglial role in normal and pathological brain and in 
targeting modulation of microglia activation for therapeutic purposes in 
neurodegenerative diseases. 
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